JoinClinicalTrials.com

Results

Hot

Post your clinical trial on JoinClinicalTrials.com

Ellijay, Georgia 30536
United States

Post your clinical trial on JoinClinicalTrials.com to reach thousands of viewer daily. Our Clinical Trial Listings have consistently proven to be an ...

• Addiction Treatment Outcome Monitoring Study

  NCT04155385

  Conditions:   Alcohol Use Disorder;   Substance Use Disorders
  Interventions:   Other: Measurement;   Other: Feedback
  Sponsors:   University of Washington;   National Institute on Alcohol Abuse and Alcoholism (NIAAA)
  Recruiting
• PET/CT Changes During Chemoimmunotherapy and Radiation Therapy in Patients With Stage IV Non-small Cell Lung Cancer

  NCT04151940

  Conditions:   Metastatic Lung Non-Small Cell Carcinoma;   Recurrent Lung Non-Small Cell Carcinoma;   Stage IV Lung Cancer AJCC v8;   Stage IVA Lung Cancer AJCC v8;   Stage IVB Lung Cancer AJCC v8
  Interventions:   Procedure: Positron Emission Tomography;   Procedure: Computed Tomography;   Drug: Chemotherapy;   Biological: Immunotherapy;   Radiation: Radiation Therapy
  Sponsors:   University of Washington;   National Cancer Institute (NCI)
  Recruiting
• Quality of Life in IPF - Patient and Physician Perceptions

  NCT04148157

  Condition:   Idiopathic Pulmonary Fibrosis
  Intervention:  
  Sponsors:   University of Washington;   Washington Research Foundation
  Recruiting
• A Cross-Functional, Population-Representative, Web-Based, Epidemiologic Study to Estimate the Prevalence and Burden of Nocturia Due to Nocturnal Polyuria in the US

  NCT04125186

  Condition:   Nocturnal Polyuria
  Interventions:   Diagnostic Test: Baseline EpiNP survey;   Diagnostic Test: Bladder diary;   Diagnostic Test: Testing of EpiNP baseline survey, bladder diary and a qualitative interview;   Other: No other intervention
  Sponsor:   Ferring Pharmaceuticals
  Recruiting
• US Study of UM171-Expanded CB in Patients With High Risk Leukemia/Myelodysplasia

  NCT04103879

  Conditions:   High Risk Hematological Malignancy;   Cord Blood Transplant
  Intervention:   Biological: ECT-001-CB (UM171-Expanded Cord Blood Transplant)
  Sponsors:   ExCellThera inc.;   Fred Hutchinson Cancer Research Center
  Recruiting
• Optimizing Pain Control in Transurethral Resection of the Prostate

  NCT04102566

  Conditions:   Pain;   BPH With Urinary Obstruction;   BPH With Urinary Obstruction With Other Lower Urinary Tract Symptoms
  Interventions:   Drug: Ibuprofen 600 mg;   Behavioral: Education
  Sponsors:   Benaroya Research Institute;   Virginia Mason Hospital/Medical Center
  Recruiting
• Comparison of Surgery and Medicine on the Impact of Diverticulitis (COSMID) Trial

  NCT04095663

  Condition:   Diverticulitis
  Interventions:   Procedure: Partial Colectomy;   Other: Medical Management
  Sponsors:   University of Washington;   Patient-Centered Outcomes Research Institute
  Recruiting
• Comparison of Prosthetic Feet for People With Syme's Amputation (XF Symes Study)

  NCT04086641

  Conditions:   Amputation;   Artificial Limb
  Interventions:   Device: Crossover foot;   Device: Energy Storing Foot
  Sponsor:   University of Washington
  Recruiting
• Mindful Body Awareness With Buprenorphine for Opioid Use Disorder Treatment

  NCT04082637

  Condition:   Opioid-use Disorder
  Intervention:   Behavioral: Mindful Awareness in Body-oriented Therapy
  Sponsors:   University of Washington;   National Center for Complementary and Integrative Health (NCCIH)
  Recruiting
• eHealth Diet and Physical Activity Program for the Improvement of Health in Rural Latino Cancer Survivors

  NCT04081298

  Conditions:   Cancer Survivor;   Malignant Neoplasm
  Interventions:   Behavioral: Health Education;   Other: Physical Activity;   Other: Text Message;   Other: Web Site;   Device: FitBit;   Device: Actigraph;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration
  Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI)
  Recruiting
• tSCI Contrast Enhanced Ultrasound Study

  NCT04056988

  Condition:   Acute Spinal Cord Injury
  Intervention:   Drug: Perflutren Lipid Microsphere
  Sponsor:   University of Washington
  Recruiting
• Comparison of Transcutaneous and Epidural Spinal Stimulation for Improving Function

  NCT04043715

  Conditions:   Spinal Cord Injuries;   Spinal Cord Diseases;   Central Nervous System Diseases;   Nervous System Diseases;   Trauma, Nervous System;   Wounds and Injuries
  Interventions:   Device: Transcutaneous spinal stimulation;   Device: Epidural spinal stimulation
  Sponsors:   University of Washington;   U.S. National Science Foundation
  Recruiting
• Autologous huMNC2-CAR44 T Cells for Breast Cancer Targeting Cleaved Form of MUC1 (MUC1*)

  NCT04020575

  Condition:   Metastatic Breast Cancer
  Interventions:   Biological: huMNC2-CAR44 CAR T cells;   Biological: huMNC2-CAR44 CAR T cells @ RP2D
  Sponsors:   Minerva Biotechnologies Corporation;   Fred Hutchinson Cancer Research Center
  Recruiting
• Online Prenatal Trial in Mindfulness Sleep Management

  NCT04016428

  Conditions:   Pregnancy Related;   Insomnia;   Depression
  Interventions:   Behavioral: OPTIMISM;   Behavioral: Sleep Education
  Sponsors:   University of Washington;   National Institute of Nursing Research (NINR)
  Recruiting
• Validation of Diagnostics to Identify Glucose-6-phosphate Dehydrogenase Activity in the US

  NCT04010695

  Condition:   G6PD Deficiency
  Intervention:   Diagnostic Test: STANDARD G6PD
  Sponsors:   PATH;   Fred Hutchinson Cancer Research Center
  Recruiting
• Inotuzumab Ozogamicin and Chemotherapy in Treating Patients With Recurrent or Refractory B-cell Acute Lymphoblastic Leukemia

  NCT03991884

  Conditions:   Recurrent B Acute Lymphoblastic Leukemia;   Recurrent B Lymphoblastic Lymphoma;   Refractory B Acute Lymphoblastic Leukemia;   Refractory B Lymphoblastic Lymphoma
  Interventions:   Drug: Etoposide;   Drug: Doxorubicin;   Drug: Doxorubicin Hydrochloride;   Drug: Vincristine;   Drug: Vincristine Sulfate;   Drug: Prednisone;   Drug: Cyclophosphamide;   Biological: Inotuzumab Ozogamicin
  Sponsors:   University of Washington;   National Cancer Institute (NCI)
  Recruiting
• Best Management of Muscle Relaxation- Objective Monitoring

  NCT03958201

  Condition:   Residual Paralysis, Post Anesthesia
  Intervention:   Drug: Protocol for Management of Muscle Relaxation With Rocuronium Using Objective Monitoring and Reversal With Neostigmine or Sugammadex
  Sponsor:   University of Washington
  Recruiting
• Modified Immune Cells (Autologous CAR T Cells) in Treating Patients With Advanced, Recurrent Platinum Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer

  NCT03907527

  Conditions:   Platinum-Resistant Fallopian Tube Carcinoma;   Platinum-Resistant Ovarian Carcinoma;   Platinum-Resistant Primary Peritoneal Carcinoma;   Progressive Disease;   Recurrent Fallopian Tube Carcinoma;   Recurrent Ovarian Carcinoma;   Recurrent Primary Peritoneal Carcinoma;   Refractory Fallopian Tube Carcinoma;   Refractory Ovarian Carcinoma;   Refractory Primary Peritoneal Carcinoma;   Stage III Fallopian Tube Cancer AJCC v8;   Stage III Ovarian Cancer AJCC v8;   Stage III Primary Peritoneal Cancer AJCC v8;   Stage IIIA Fallopian Tube Cancer AJCC v8;   Stage IIIA Ovarian Cancer AJCC v8;   Stage IIIA Primary Peritoneal Cancer AJCC v8;   Stage IIIA1 Fallopian Tube Cancer AJCC v8;   Stage IIIA1 Ovarian Cancer AJCC v8;   Stage IIIA2 Fallopian Tube Cancer AJCC v8;   Stage IIIA2 Ovarian Cancer AJCC v8;   Stage IIIB Fallopian Tube Cancer AJCC v8;   Stage IIIB Ovarian Cancer AJCC v8;   Stage IIIB Primary Peritoneal Cancer AJCC v8;   Stage IIIC Fallopian Tube Cancer AJCC v8;   Stage IIIC Ovarian Cancer AJCC v8;   Stage IIIC Primary Peritoneal Cancer AJCC v8;   Stage IV Fallopian Tube Cancer AJCC v8;   Stage IV Ovarian Cancer AJCC v8;   Stage IV Primary Peritoneal Cancer AJCC v8;   Stage IVA Fallopian Tube Cancer AJCC v8;   Stage IVA Ovarian Cancer AJCC v8;   Stage IVA Primary Peritoneal Cancer AJCC v8;   Stage IVB Fallopian Tube Cancer AJCC v8;   Stage IVB Ovarian Cancer AJCC v8;   Stage IVB Primary Peritoneal Cancer AJCC v8
  Intervention:   Biological: PRGN-3005 UltraCAR-T cells
  Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI);   Precigen, Inc
  Recruiting
• Management of Pleural Space Infections

  NCT03873766

  Conditions:   Empyema, Pleural;   Parapneumonic Effusion
  Interventions:   Drug: Intrapleural Medications;   Procedure: Surgery;   Procedure: Pleural Sampling;   Procedure: Pleural fluid drainage;   Radiation: Protocol Image #1;   Other: Surgical Consultation;   Radiation: Protocol Image #2: Chest X-ray PA/Lateral;   Behavioral: Quality of Life
  Sponsor:   Swedish Medical Center
  Recruiting
• TAP Blocks vs. IV Lidocaine for Kidney Transplants

  NCT03843879

  Condition:   Postoperative Pain
  Interventions:   Procedure: Transversus Abdominis Plane Block;   Drug: Intravenous Lidocaine
  Sponsor:   Benaroya Research Institute
  Recruiting
• Poststroke Depression in Hemorrhagic Stroke

  NCT03826875

  Conditions:   Stroke Hemorrhagic;   Depression
  Interventions:   Drug: Fluoxetine;   Drug: Placebo
  Sponsor:   University of Washington
  Recruiting
• MBCT and CBT for Chronic Pain in Multiple Sclerosis

  NCT03782246

  Condition:   Multiple Sclerosis
  Interventions:   Behavioral: MBCT;   Behavioral: CBT
  Sponsors:   University of Washington;   National Multiple Sclerosis Society
  Recruiting
• Pilot Trial of Resistant Starch in Stage I-III Colorectal Cancer Survivors

  NCT03781778

  Conditions:   Colon Cancer;   Rectal Cancer;   Cancer Survivor;   Colorectal Adenocarcinoma;   Stage I Colorectal Cancer AJCC v8;   Stage II Colorectal Cancer AJCC v8;   Stage IIA Colorectal Cancer AJCC v8;   Stage IIB Colorectal Cancer AJCC v8;   Stage IIC Colorectal Cancer AJCC v8;   Stage III Colorectal Cancer AJCC v8;   Stage IIIA Colorectal Cancer AJCC v8;   Stage IIIB Colorectal Cancer AJCC v8;   Stage IIIC Colorectal Cancer AJCC v8
  Interventions:   Other: Dietary Intervention (resistant starch);   Other: Dietary Intervention (regular starch);   Other: Questionnaire Administration
  Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI)
  Recruiting
• Acute Exercise Intervention in Reducing Breast Cancer Risk in Healthy Participants

  NCT03779867

  Conditions:   Healthy Subject;   Breast Cancer Female
  Interventions:   Behavioral: Exercise Intervention;   Other: Resting;   Other: Biomarker Analysis;   Other: Questionnaire Administration
  Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI)
  Recruiting
• Umbralisib and Pembrolizumab in Treating Patients With Relapsed or Refractory Classical Hodgkin Lymphoma

  NCT03776864

  Condition:   Hodgkin's Lymphoma
  Interventions:   Biological: Pembrolizumab;   Drug: Umbralisib
  Sponsors:   University of Washington;   National Cancer Institute (NCI)
  Recruiting
• Gene-Modified Immune Cells (FH-MCVA2TCR) in Treating Patients With Metastatic or Unresectable Merkel Cell Cancer

  NCT03747484

  Condition:   Other Skin
  Interventions:   Biological: Autologous MCPyV-specific HLA-A02-restricted TCR-transduced CD4+ and CD8+ T-cells FH-MCVA2TCR;   Drug: Avelumab;   Radiation: Radiation Therapy;   Biological: Pembrolizumab
  Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI);   Bluebird Biosciences
  Recruiting
• Strategies to Improve Pain and Enjoy Life

  NCT03743402

  Condition:   Chronic Pain
  Interventions:   Behavioral: Pain self-management training;   Behavioral: video education, motivational interviewing;   Drug: voluntary self-paced opioid taper;   Drug: prescribing guidance for primary care provider;   Other: usual care
  Sponsors:   University of Washington;   Kaiser Permanente
  Recruiting
• Occupational Therapist-Led Work Intervention in Facilitating Work Maintenance or Re-entry to the Workforce in Patients With Stage I to III Breast Cancer Undergoing Chemotherapy

  NCT03723863

  Conditions:   Breast Cancer Stage I;   Breast Cancer Stage III;   Breast Cancer Stage II;   Breast Cancer Stage IIA;   Breast Cancer Stage IIB;   Breast Cancer Stage IIIA;   Breast Cancer Stage IIIB;   Breast Cancer Stage IIIc;   Breast Cancer
  Intervention:   Behavioral: Occupational Therapy
  Sponsor:   University of Washington
  Recruiting
• Back on Track to Healthy Living Study

  NCT03687762

  Condition:   Chronic Pain
  Interventions:   Behavioral: Cognitive Therapy (CT);   Behavioral: Mindfulness Meditation (MM);   Behavioral: Activation Skills (AS)
  Sponsors:   University of Washington;   Rush University;   Medical University of South Carolina;   The University of Queensland;   National Center for Complementary and Integrative Health (NCCIH)
  Recruiting
• 211At-BC8-B10 and Donor Stem Cell Transplant in Treating Relapsed or Refractory AML, ALL, or Myelodysplastic Syndrome

  NCT03670966

  Conditions:   Acute Lymphoblastic Leukemia in Remission;   Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome;   Acute Myeloid Leukemia in Remission;   CD45-Positive Neoplastic Cells Present;   Chronic Myelomonocytic Leukemia;   High Risk Myelodysplastic Syndrome;   Myelodysplastic Syndrome With Excess Blasts;   Myeloproliferative Neoplasm;   Recurrent Acute Lymphoblastic Leukemia;   Recurrent Acute Myeloid Leukemia;   Refractory Acute Lymphoblastic Leukemia;   Refractory Acute Myeloid Leukemia
  Interventions:   Biological: Astatine At 211 Anti-CD45 Monoclonal Antibody BC8-B10;   Drug: Fludarabine;   Drug: Cyclophosphamide;   Radiation: Total-Body Irradiation;   Procedure: Peripheral Blood Stem Cell Transplantation;   Procedure: Bone Marrow Transplantation;   Drug: Tacrolimus;   Drug: Mycophenolate Mofetil;   Drug: Sirolimus;   Biological: Granulocyte Colony-Stimulating Factor
  Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI)
  Recruiting
• Itacitinib in Treating Patients With Refractory Metastatic/Advanced Soft Soft Tissue Sarcomas

  NCT03670069

  Conditions:   Metastatic Leiomyosarcoma;   Metastatic Synovial Sarcoma;   Metastatic Undifferentiated Pleomorphic Sarcoma;   Advanced Myxoid Liposarcoma;   Advanced Soft Tissue Sarcoma;   Metastatic Myxoid Liposarcoma;   Metastatic Round Cell Liposarcoma;   Metastatic Soft Tissue Sarcoma;   Refractory Leiomyosarcoma;   Refractory Myxoid Liposarcoma;   Refractory Round Cell Liposarcoma;   Refractory Soft Tissue Sarcoma;   Refractory Synovial Sarcoma;   Refractory Undifferentiated Pleomorphic Sarcoma
  Interventions:   Drug: Itacitinib;   Other: Laboratory Biomarker Analysis
  Sponsors:   Fred Hutchinson Cancer Research Center;   Incyte Corporation;   National Cancer Institute (NCI)
  Recruiting
• The Effects of Moderate Exercise on Distress, Quality of Life, and Biomarkers of Angiogenesis and Chronic Stress in Ovarian Cancer Survivors

  NCT03641287

  Conditions:   Ovarian Cancer;   Fallopian Tube Adenocarcinoma;   Fallopian Tube Carcinosarcoma;   Fallopian Tube Clear Cell Adenocarcinoma;   Fallopian Tube Endometrioid Adenocarcinoma;   Fallopian Tube Mucinous Adenocarcinoma;   Fallopian Tube Serous Adenocarcinoma;   Fallopian Tube Transitional Cell Carcinoma;   Fallopian Tube Undifferentiated Carcinoma;   Malignant Ovarian Brenner Tumor;   Ovarian Adenocarcinoma;   Ovarian Carcinosarcoma;   Ovarian Clear Cell Adenocarcinoma;   Ovarian Endometrioid Adenocarcinoma;   Ovarian Mucinous Adenocarcinoma;   Ovarian Seromucinous Carcinoma;   Ovarian Serous Adenocarcinoma;   Ovarian Transitional Cell Carcinoma;   Ovarian Undifferentiated Carcinoma;   Primary Peritoneal Serous Adenocarcinoma;   Primary Peritoneal Carcinosarcoma;   Primary Peritoneal Transitional Cell Carcinoma
  Interventions:   Other: Exercise Counseling;   Other: Aerobic Exercise;   Other: Physiological Support;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration;   Other: Best Practice
  Sponsors:   University of Washington;   National Cancer Institute (NCI)
  Recruiting
• Genetic Influences on Response to Gait Rehabilitation in Parkinson's Disease

  NCT03607695

  Condition:   Parkinson's Disease
  Intervention:   Other: Gait training
  Sponsors:   VA Office of Research and Development;   University of Washington
  Recruiting
• Lavage of the Uterine Cavity for Diagnosis of Ovarian Cancer

  NCT03606486

  Conditions:   High Grade Ovarian Serous Adenocarcinoma;   Stage III Ovarian Cancer AJCC v8;   Stage IIIA Ovarian Cancer AJCC v8;   Stage IIIA1 Ovarian Cancer AJCC v8;   Stage IIIA2 Ovarian Cancer AJCC v8;   Stage IIIB Ovarian Cancer AJCC v8;   Stage IIIC Ovarian Cancer AJCC v8;   Stage IV Ovarian Cancer AJCC v8;   Stage IVA Ovarian Cancer AJCC v8;   Stage IVB Ovarian Cancer AJCC v8
  Interventions:   Other: Biospecimen Collection;   Other: Laboratory Biomarker Analysis;   Other: Lavage;   Other: Pap Smear
  Sponsors:   University of Washington;   National Cancer Institute (NCI);   Minnesota Ovarian Cancer Alliance
  Recruiting
• Enhanced E-cigarette Coaching Intervention for Dual Users of Cigarettes and E-cigarettes

  NCT03575468

  Condition:   Smoking Cessation
  Interventions:   Behavioral: Enhanced E-cigarette Coaching;   Behavioral: Quitline treatment as usual
  Sponsors:   Alere Wellbeing;   University of Oklahoma;   SRI International;   H. Lee Moffitt Cancer Center and Research Institute
  Recruiting
• Hypnosis and Meditation for Cancer Pain

  NCT03558594

  Conditions:   Pain Related to Cancer;   Cancer of Head and Neck
  Interventions:   Behavioral: Hypnosis;   Behavioral: Mindfulness
  Sponsor:   VA Puget Sound Health Care System
  Recruiting
• Auto Control of Volume Management for Limb Loss

  NCT03550118

  Condition:   Lower Limb Amputation Below Knee (Injury)
  Intervention:   Device: Adjustable socket
  Sponsor:   University of Washington
  Recruiting
• Predicting Responses to PTSD Treatment With Iris and Cardiovascular Tests

  NCT03539614

  Condition:   Posttraumatic Stress Disorder
  Interventions:   Drug: Prazosin;   Drug: Placebo
  Sponsor:   VA Office of Research and Development
  Recruiting
• Pivot-Flex Foot: Optimal Coupling Ratio Between Transverse and Sagittal-plane Motions Using a Torsionally Adaptive Prosthesis for Individuals With Lower Limb Amputation

  NCT03532100

  Condition:   Lower Extremity Amputation
  Interventions:   Device: Torsionally adaptive prosthesis with 0:1 coupling ratio;   Device: Torsionally adaptive prosthesis with 1:6 coupling ratio;   Device: Torsionally adaptive prosthesis with 1:4 coupling ratio;   Device: Torsionally adaptive prosthesis with 1:3 coupling ratio;   Device: Torsionally adaptive prosthesis with 1:2 coupling ratio
  Sponsor:   VA Office of Research and Development
  Recruiting
• Gemtuzumab Ozogamicin With G-CSF, Cladribine, Cytarabine and Mitoxantrone in Treating Participants With Previously Untreated Acute Myeloid Leukemia or High-Grade Myeloid Neoplasm

  NCT03531918

  Conditions:   Acute Myeloid Leukemia;   High-Grade Myeloid Neoplasm;   Blasts 10 Percent or More of Bone Marrow Nucleated Cells;   Blasts 10 Percent or More of Peripheral Blood White Cells;   High Grade Myeloid Neoplasm
  Interventions:   Drug: Cladribine;   Drug: Cytarabine;   Drug: Gemtuzumab Ozogamicin;   Biological: Granulocyte Colony-Stimulating Factor;   Other: Laboratory Biomarker Analysis;   Drug: Mitoxantrone Hydrochloride
  Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI);   Pfizer
  Recruiting
• Do Rocker Bottom Shoes and Ankle-Foot Orthoses Reduce Pain and Improve Mobility for Ankle Osteoarthritis Patients

  NCT03524729

  Conditions:   Ankle Osteoarthritis;   Healthy Ankles
  Interventions:   Device: Rocker bottom shoe;   Device: Ankle foot orthosis;   Device: Standard walking shoe
  Sponsor:   VA Office of Research and Development
  Recruiting
• Durvalumab, Tremelimumab and Hypofractionated Radiation Therapy in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

  NCT03522584

  Conditions:   Metastatic Head and Neck Squamous Cell Carcinoma;   Recurrent Head and Neck Squamous Cell Carcinoma
  Interventions:   Biological: Durvalumab;   Other: Laboratory Biomarker Analysis;   Radiation: Stereotactic Body Radiation Therapy;   Biological: Tremelimumab;   Procedure: Hypofractionated Image-Guided Radiation Therapy
  Sponsors:   University of Washington;   National Cancer Institute (NCI)
  Recruiting
• Selecting Effective Combinations of Treatment for Low Back Pain

  NCT03520387

  Condition:   Low Back Pain
  Interventions:   Procedure: Lumbar medial branch nerve radiofrequency ablation (LRFA);   Procedure: Simulated LRFA with targeted steroid injections;   Behavioral: AcTIVE-CBT;   Behavioral: TBSCE
  Sponsor:   VA Office of Research and Development
  Recruiting
• Testosterone and Olaparib in Treating Participants With Castration-Resistant Prostate Cancer

  NCT03516812

  Conditions:   Castration Levels of Testosterone;   Castration-Resistant Prostate Carcinoma;   Prostate Adenocarcinoma;   PSA Level Greater Than or Equal to One;   PSA Progression
  Interventions:   Other: Laboratory Biomarker Analysis;   Drug: Olaparib;   Other: Quality-of-Life Assessment;   Other: Survey Administration;   Drug: Testosterone Enanthate;   Drug: Testosterone Cypionate
  Sponsors:   University of Washington;   National Cancer Institute (NCI)
  Recruiting
• Pembrolizumab in Untreated B-Cell Non-Hodgkin Lymphoproliferative Diseases

  NCT03498612

  Conditions:   B-Cell Non-Hodgkin Lymphoma;   Follicular Lymphoma;   Indolent Non-Hodgkin Lymphoma;   Marginal Zone Lymphoma
  Interventions:   Other: Laboratory Biomarker Analysis;   Biological: Pembrolizumab
  Sponsors:   University of Washington;   National Cancer Institute (NCI)
  Recruiting
• Docetaxel, Carboplatin, and Rucaparib Camsylate in Treating Patients With Metastatic Castration Resistant Prostate Cancer With Homologous Recombination DNA Repair Deficiency

  NCT03442556

  Conditions:   ATM Gene Mutation;   BRCA1 Gene Mutation;   BRCA2 Gene Mutation;   Castration Levels of Testosterone;   Castration-Resistant Prostate Carcinoma;   Homologous Recombination Deficiency;   Prostate Carcinoma Metastatic in the Bone;   PSA Level Greater Than or Equal to Two;   PSA Progression;   Stage IV Prostate Adenocarcinoma AJCC v7
  Interventions:   Drug: Carboplatin;   Drug: Docetaxel;   Other: Laboratory Biomarker Analysis;   Drug: Rucaparib Camsylate;   Drug: Rucaparib
  Sponsors:   University of Washington;   National Cancer Institute (NCI)
  Recruiting
• Improving the Detection, Classification and Treatment of Misaligned Arthritic Ankles

  NCT03440008

  Condition:   Ankle Osteoarthritis
  Interventions:   Other: Dynamic 3D bone motion capture;   Device: wedged insole
  Sponsor:   VA Office of Research and Development
  Recruiting
• Fluorescence QRH-882260 Peptide Imaging in the Bile Duct

  NCT03438435

  Condition:   Cholangiocarcinoma
  Intervention:   Drug: QRH-882260 Heptapeptide
  Sponsors:   D. Kim Turgeon, MD;   University of Washington
  Recruiting
• Microprocessor Knees in Early Rehabilitation

  NCT03433300

  Condition:   Amputation
  Interventions:   Device: Ottobock Kenevo/C-Leg;   Device: Ottobock 3R60/3R62
  Sponsors:   University of Washington;   United States Department of Defense;   Otto Bock Healthcare Products GmbH
  Recruiting
• Rituximab and Pembrolizumab in Treating Patients With Relapsed or Refractory Follicular Lymphoma or Diffuse Large B Cell Lymphoma

  NCT03401853

  Conditions:   Recurrent Diffuse Large B-Cell Lymphoma;   Recurrent Follicular Lymphoma;   Refractory Diffuse Large B-Cell Lymphoma;   Refractory Follicular Lymphoma
  Interventions:   Other: Laboratory Biomarker Analysis;   Biological: Pembrolizumab;   Biological: Rituximab
  Sponsors:   University of Washington;   National Cancer Institute (NCI)
  Recruiting
• Immunotherapy With BCMA CAR-T Cells in Treating Patients With BCMA Positive Relapsed or Refractory Multiple Myeloma

  NCT03338972

  Conditions:   Recurrent Plasma Cell Myeloma;   Refractory Plasma Cell Myeloma
  Interventions:   Biological: Autologous Anti-BCMA-CAR-expressing CD4+/CD8+ T-lymphocytes FCARH143;   Drug: Cyclophosphamide;   Drug: Fludarabine;   Other: Laboratory Biomarker Analysis;   Procedure: Leukapheresis
  Sponsors:   Fred Hutchinson Cancer Research Center;   Juno Therapeutics, Inc.;   National Cancer Institute (NCI)
  Recruiting
• Doxorubicin Hydrochloride, Pembrolizumab, Vinblastine, and Dacarbazine in Treating Patients With Classical Hodgkin Lymphoma

  NCT03331341

  Condition:   Classical Hodgkin Lymphoma
  Interventions:   Drug: Dacarbazine;   Drug: Doxorubicin Hydrochloride;   Other: Laboratory Biomarker Analysis;   Biological: Pembrolizumab;   Drug: Vinblastine;   Drug: Doxorubicin
  Sponsors:   University of Washington;   National Cancer Institute (NCI);   Merck Sharp & Dohme Corp.
  Recruiting
• A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas

  NCT03277729

  Conditions:   CD20 Positive;   Recurrent B-Cell Non-Hodgkin Lymphoma;   Recurrent Chronic Lymphocytic Leukemia;   Recurrent Diffuse Large B-Cell Lymphoma;   Recurrent Follicular Lymphoma;   Recurrent Lymphoplasmacytic Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Refractory B-Cell Non-Hodgkin Lymphoma;   Refractory Diffuse Large B-Cell Lymphoma;   Refractory Follicular Lymphoma;   Refractory Lymphoplasmacytic Lymphoma;   Refractory Mantle Cell Lymphoma;   Refractory Transformed Non-Hodgkin Lymphoma;   Recurrent Transformed B-cell Non-Hodgkin Lymphoma;   Recurrent Transformed Chronic Lymphocytic Leukemia;   Refractory Marginal Zone Lymphoma;   Refractory Transformed B-cell Non-Hodgkin Lymphoma;   Refractory Transformed Chronic Lymphocytic Leukemia
  Interventions:   Biological: Chimeric Antigen Receptor T-Cell Therapy;   Drug: Cyclophosphamide;   Drug: Fludarabine;   Other: Laboratory Biomarker Analysis;   Procedure: Leukapheresis;   Drug: Fludarabine Phosphate
  Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI)
  Recruiting
• Aldesleukin and Pembrolizumab in Treating Patients With Advanced or Metastatic Kidney Cancer

  NCT03260504

  Conditions:   Clear Cell Renal Cell Carcinoma;   Stage III Renal Cell Cancer;   Stage IV Renal Cell Cancer
  Interventions:   Biological: Aldesleukin;   Biological: Pembrolizumab
  Sponsors:   University of Washington;   National Cancer Institute (NCI)
  Recruiting
• Prazosin and CSF Biomarkers in mTBI

  NCT03221751

  Condition:   Dementia
  Interventions:   Drug: prazosin hydrochloride;   Drug: placebo
  Sponsor:   VA Office of Research and Development
  Recruiting
• Bioimpedance as a Diagnostic Tool for Assessing the Need for Socket Modification in Transtibial Amputees

  NCT03164356

  Condition:   Transtibial Amputee
  Intervention:   Other: Socket Modification Regime
  Sponsor:   University of Washington
  Recruiting
• 211^At-BC8-B10 Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome, or Mixed-Phenotype Acute Leukemia

  NCT03128034

  Conditions:   Acute Lymphoblastic Leukemia in Remission;   Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome;   Acute Myeloid Leukemia in Remission;   High Risk Myelodysplastic Syndrome;   Chronic Myelomonocytic Leukemia;   Myelodysplastic Syndrome With Excess Blasts;   Recurrent Acute Myeloid Leukemia;   Refractory Acute Lymphoblastic Leukemia;   Recurrent Acute Lymphoblastic Leukemia;   Recurrent Mixed Phenotype Acute Leukemia;   Refractory Acute Myeloid Leukemia;   Refractory Mixed Phenotype Acute Leukemia
  Interventions:   Drug: Cyclosporine;   Drug: Fludarabine Phosphate;   Other: Laboratory Biomarker Analysis;   Drug: Mycophenolate Mofetil;   Procedure: Peripheral Blood Stem Cell Transplantation;   Other: Pharmacological Study;   Radiation: Pretargeted Radioimmunotherapy;   Drug: Sirolimus;   Radiation: Total-Body Irradiation;   Device: Fludarabine
  Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI)
  Recruiting
• huJCAR014 CAR-T Cells in Treating Adult Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma or Acute Lymphoblastic Leukemia

  NCT03103971

  Conditions:   Adult B Acute Lymphoblastic Leukemia;   BCL2 Gene Rearrangement;   BCL6 Gene Rearrangement;   CD19 Positive;   Diffuse Large B-Cell Lymphoma, Not Otherwise Specified;   MYC Gene Rearrangement;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent B-Cell Non-Hodgkin Lymphoma;   Recurrent Diffuse Large B-Cell Lymphoma;   Recurrent Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma;   Refractory Adult Acute Lymphoblastic Leukemia;   Refractory B-Cell Non-Hodgkin Lymphoma;   Refractory Diffuse Large B-Cell Lymphoma;   Refractory Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma;   Recurrent Transformed Non-Hodgkin Lymphoma
  Interventions:   Biological: Autologous Human Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+/CD8+ T-lymphocytes;   Drug: Cyclophosphamide;   Drug: Fludarabine;   Other: Laboratory Biomarker Analysis;   Procedure: Leukapheresis;   Other: Pharmacological Study
  Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI)
  Recruiting
• Avelumab and Trabectedin in Treating Patients With Liposarcoma or Leiomyosarcoma That is Metastatic or Cannot Be Removed by Surgery

  NCT03074318

  Conditions:   Metastatic Leiomyosarcoma;   Metastatic Liposarcoma;   Unresectable Leiomyosarcoma;   Unresectable Liposarcoma
  Interventions:   Drug: Avelumab;   Drug: Trabectedin
  Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI)
  Recruiting
• Groups for Regaining Our Wellbeing

  NCT03058952

  Conditions:   Gulf War;   Fatigue;   Pain;   Depression
  Interventions:   Behavioral: Mindfulness-Based Stress Reduction;   Behavioral: Chronic Disease Self-Management Program
  Sponsor:   VA Office of Research and Development
  Recruiting
• HPV Vaccine Therapy in Interrupting Progression in Patients With High-Grade Vulvar or Anal Lesions

  NCT03051516

  Conditions:   High Grade Anal Canal Squamous Intraepithelial Neoplasia;   Vulvar High Grade Squamous Intraepithelial Lesion
  Interventions:   Other: Laboratory Biomarker Analysis;   Other: Placebo;   Other: Questionnaire Administration;   Biological: Recombinant Human Papillomavirus Nonavalent Vaccine
  Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI)
  Recruiting
• Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

  NCT03023046

  Conditions:   Acute Lymphoblastic Leukemia;   Lymphoblastic Lymphoma
  Interventions:   Drug: Cyclophosphamide;   Drug: Dasatinib;   Drug: Doxorubicin;   Drug: Etoposide;   Drug: Imatinib Mesylate;   Other: Laboratory Biomarker Analysis;   Drug: Prednisone;   Biological: Rituximab;   Drug: Vincristine Sulfate
  Sponsors:   University of Washington;   National Cancer Institute (NCI)
  Recruiting
• Higher or Lower Dose Cladribine, Cytarabine, and Mitoxantrone in Treating Medically Less Fit Patients With Newly Diagnosed Acute Myeloid Leukemia or Myeloid Neoplasm

  NCT03012672

  Conditions:   Acute Leukemia of Ambiguous Lineage;   Acute Myeloid Leukemia;   Myeloid Neoplasm
  Interventions:   Drug: Cladribine;   Drug: Cytarabine;   Biological: Granulocyte Colony-Stimulating Factor;   Drug: Mitoxantrone Hydrochloride;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration
  Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI)
  Recruiting
• Patient Fitness and Body Composition During Hematopoietic Stem Cell Transplantation

  NCT02990130

  Condition:   Hematologic Malignancy
  Intervention:   Other: Observational
  Sponsor:   Garcia, Jose M., MD, PhD
  Recruiting
• Metabolic and QOL Effects of GH Treatment in Patients With TBI and AGHD

  NCT02988687

  Condition:   Adult-Onset Growth Hormone Deficiency
  Intervention:  
  Sponsor:   Garcia, Jose M., MD, PhD
  Recruiting
• Strong Men, Strong Communities Diabetes Risk Reduction in American Indian Men

  NCT02953977

  Condition:   Diabetes
  Intervention:   Behavioral: Diabetes Prevention Program
  Sponsor:   Washington State University
  Recruiting
• Deferasirox in Treating Patients With Very Low, Low, or Intermediate-Risk Red Blood Cell Transfusion Dependent Anemia or Myelodysplastic Syndrome

  NCT02943668

  Conditions:   Anemia;   Myelodysplastic Syndrome
  Interventions:   Drug: Deferasirox;   Other: Laboratory Biomarker Analysis
  Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI);   Novartis Pharmaceuticals
  Recruiting
• Early Allogeneic Hematopoietic Cell Transplantation in Treating Patients With Relapsed or Refractory High-Grade Myeloid Neoplasms

  NCT02756572

  Conditions:   Blasts 10 Percent or More of Bone Marrow Nucleated Cells;   Chronic Myelomonocytic Leukemia-2;   High Grade Malignant Neoplasm;   Myelodysplastic Syndrome;   Myelodysplastic Syndrome With Excess Blasts-2;   Myeloid Neoplasm;   Previously Treated Myelodysplastic Syndrome;   Recurrent Acute Myeloid Leukemia;   Refractory Acute Myeloid Leukemia
  Interventions:   Drug: Cladribine;   Drug: Cyclosporine;   Drug: Cytarabine;   Biological: Filgrastim;   Drug: Fludarabine Phosphate;   Procedure: Allogeneic Hematopoietic Stem Cell Transplantation;   Other: Laboratory Biomarker Analysis;   Drug: Melphalan;   Drug: Mitoxantrone Hydrochloride;   Drug: Mycophenolate Mofetil;   Other: Questionnaire Administration;   Drug: Sirolimus;   Radiation: Total-Body Irradiation;   Drug: Melphalan Hydrochloride
  Sponsors:   University of Washington;   National Cancer Institute (NCI)
  Recruiting
• JCAR014 and Durvalumab in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

  NCT02706405

  Conditions:   BCL2 Gene Rearrangement;   BCL6 Gene Rearrangement;   CD19 Positive;   Diffuse Large B-Cell Lymphoma, Not Otherwise Specified;   High-Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements;   MYC Gene Rearrangement;   Recurrent Diffuse Large B-Cell Lymphoma;   Recurrent Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma;   Refractory Diffuse Large B-Cell Lymphoma;   Refractory Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma
  Interventions:   Biological: Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+/CD8+ Central Memory T-lymphocytes JCAR014;   Drug: Cyclophosphamide;   Biological: Durvalumab;   Drug: Fludarabine Phosphate;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study
  Sponsors:   Fred Hutchinson Cancer Research Center;   AstraZeneca;   Juno Therapeutics, Inc.;   MedImmune LLC;   National Cancer Institute (NCI)
  Recruiting
• Docetaxel and Carboplatin in Treating Patients With Metastatic, Castration Resistant Prostate Cancer Containing Inactivated Genes in the BRCA 1/2 Pathway

  NCT02598895

  Conditions:   Castration Levels of Testosterone;   Castration-Resistant Prostate Carcinoma;   Metastatic Prostate Carcinoma;   Prostate Carcinoma Metastatic in the Bone;   PSA Progression;   Stage IV Prostate Cancer
  Interventions:   Drug: Carboplatin;   Drug: Docetaxel;   Other: Laboratory Biomarker Analysis
  Sponsors:   University of Washington;   National Cancer Institute (NCI)
  Recruiting
• Sirolimus, Docetaxel, and Carboplatin in Treating Patients With Metastatic Castration-Resistant Prostate Cancer

  NCT02565901

  Conditions:   Castration Levels of Testosterone;   Castration-Resistant Prostate Carcinoma;   Metastatic Prostate Carcinoma;   Prostate Carcinoma Metastatic in the Bone;   PSA Level Greater Than or Equal to Two;   PSA Progression;   Stage IV Prostate Cancer AJCC v7
  Interventions:   Drug: Carboplatin;   Drug: Docetaxel;   Other: Laboratory Biomarker Analysis;   Drug: Sirolimus
  Sponsors:   University of Washington;   National Cancer Institute (NCI)
  Recruiting
• Diet and Exercise Program to Promote Weight Loss and Improve Health in Men With Low- or Low-Intermediate-Risk Prostate Cancer

  NCT02454517

  Conditions:   Obesity;   Overweight;   Prostate Adenocarcinoma;   Stage I Prostate Cancer AJCC V7;   Stage IIA Prostate Cancer AJCC v7
  Interventions:   Behavioral: Behavioral Dietary Intervention;   Behavioral: Exercise Intervention;   Other: Informational Intervention;   Other: Laboratory Biomarker Analysis;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration
  Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI)
  Recruiting
• Ixazomib Citrate and Rituximab in Treating Patients With Indolent B-cell Non-Hodgkin Lymphoma

  NCT02339922

  Conditions:   Chronic Lymphocytic Leukemia;   Follicular Lymphoma;   Lymphoplasmacytic Lymphoma;   Mantle Cell Lymphoma;   Marginal Zone Lymphoma;   Recurrent Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue;   Refractory Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue;   Small Lymphocytic Lymphoma;   Waldenstrom Macroglobulinemia
  Interventions:   Drug: Ixazomib Citrate;   Other: Laboratory Biomarker Analysis;   Biological: Rituximab
  Sponsors:   University of Washington;   National Cancer Institute (NCI)
  Recruiting
• Stereotactic Body Radiotherapy for Stage I-III Prostate Cancer

  NCT02334579

  Conditions:   Prostate Cancer;   Prostatic Cancer;   Prostate Neoplasms;   Prostatic Neoplasms;   Cancer of the Prostate
  Intervention:   Radiation: CyberKnife Stereotactic Radiosurgery
  Sponsor:   Swedish Medical Center
  Recruiting
• Chronic Postconcussive Headache: A Placebo-Controlled Treatment Trial of Prazosin

  NCT02266329

  Conditions:   Posttraumatic Headache;   Combat Disorders;   Post Concussion Syndrome;   Headache;   Mild Traumatic Brain Injury;   Posttraumatic Migraine
  Interventions:   Drug: prazosin hydrochloride;   Drug: placebo
  Sponsor:   VA Office of Research and Development
  Recruiting
• Brentuximab Vedotin, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma

  NCT02227199

  Conditions:   Recurrent Adult Hodgkin Lymphoma;   Refractory Hodgkin Lymphoma;   TNFRSF8 Positive
  Interventions:   Drug: Brentuximab Vedotin;   Drug: Carboplatin;   Drug: Etoposide;   Drug: Ifosfamide;   Other: Laboratory Biomarker Analysis
  Sponsors:   University of Washington;   National Cancer Institute (NCI)
  Recruiting
• Project to Improve Communication About Serious Illness - Pilot Study

  NCT03746392

  Conditions:   Malignant Neoplasm;   Leukemia, Lymphocytic, Chronic, B-Cell;   Lung Disease Chronic;   Congestive Heart Failure;   Liver Failures, Chronic;   Renal Insufficiency, Chronic;   Dementia;   Diabetes Complications;   Peripheral Vascular Disease;   Frail Elderly
  Intervention:   Behavioral: Jumpstart Intervention
  Sponsor:   University of Washington
  Recruiting
• Vaccine Therapy in Treating Patients With HER2-Negative Stage III-IV Breast Cancer

  NCT02157051

  Conditions:   HER2/Neu Negative;   Recurrent Breast Carcinoma;   Stage IIIA Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer;   Stage IV Breast Cancer;   Stage III Breast Cancer
  Interventions:   Biological: CD105/Yb-1/SOX2/CDH3/MDM2-polyepitope Plasmid DNA Vaccine;   Other: Laboratory Biomarker Analysis
  Sponsors:   University of Washington;   United States Department of Defense;   National Cancer Institute (NCI)
  Recruiting
• TBI Care: Collaborative Care for Pain After Traumatic Brain Injury (TBI)

  NCT03523923

  Conditions:   Brain Injuries, Traumatic;   Chronic Pain;   Post-Traumatic Headache
  Intervention:   Behavioral: Collaborative Care
  Sponsors:   University of Washington;   National Institute on Disability, Independent Living, and Rehabilitation Research
  Recruiting
• Brentuximab Vedotin With or Without Nivolumab in Treating Patients With Relapsed or Refractory CD30+ Lymphoma

  NCT01703949

  Conditions:   CD30-Positive Neoplastic Cells Present;   Recurrent Hodgkin Lymphoma;   Recurrent Non-Hodgkin Lymphoma;   Refractory Hodgkin Lymphoma;   Refractory Non-Hodgkin Lymphoma
  Interventions:   Drug: Brentuximab Vedotin;   Other: Laboratory Biomarker Analysis;   Biological: Nivolumab
  Sponsors:   University of Washington;   National Cancer Institute (NCI)
  Recruiting
• Sulfur Colloid SPECT/CT in Measuring Liver Function in Patients With Primary or Metastatic Liver Cancer Undergoing Radiation Therapy or Surgery

  NCT02881554

  Conditions:   Hepatocellular Carcinoma;   Intrahepatic Cholangiocarcinoma;   Stage IV Liver Cancer;   Stage IVA Liver Cancer;   Stage IVB Liver Cancer;   Vascular Thrombosis
  Interventions:   Procedure: Computed Tomography;   Procedure: Single Photon Emission Computed Tomography;   Drug: Technetium Tc-99m Sulfur Colloid
  Sponsors:   University of Washington;   National Cancer Institute (NCI)
  Recruiting
• FLARE RT for Patients With Stage IIB-IIIB Non-small Cell Lung Cancer: Personalizing Radiation Therapy Using PET/CT and SPECT/CT Imaging

  NCT02773238

  Conditions:   Stage IIB Non-Small Cell Lung Carcinoma AJCC v7;   Stage IIIA Non-Small Cell Lung Cancer AJCC v7;   Stage IIIB Non-Small Cell Lung Cancer AJCC v7
  Interventions:   Procedure: Computed Tomography;   Radiation: Fludeoxyglucose F-18;   Other: Laboratory Biomarker Analysis;   Procedure: Positron Emission Tomography;   Radiation: Radiation Therapy;   Procedure: Single Photon Emission Computed Tomography;   Radiation: Technetium Tc-99m Albumin Aggregated;   Radiation: Technetium Tc-99m Sulfur Colloid
  Sponsors:   University of Washington;   National Cancer Institute (NCI)
  Recruiting
• Orthotic Dose Response Study

  NCT02629731

  Conditions:   Ankle Osteoarthritis;   Flat Foot or Pes Planus
  Intervention:   Device: custom orthoses with varying degrees of hindfoot posting
  Sponsors:   VA Office of Research and Development;   University of Washington
  Recruiting
• Collecting and Studying Blood and Tissue Samples From Patients With Locally Recurrent or Metastatic Prostate or Bladder/Urothelial Cancer

  NCT01050504

  Conditions:   Healthy Control;   Localized Urothelial Carcinoma of the Renal Pelvis and Ureter;   Metastatic Malignant Neoplasm in the Bone;   Metastatic Malignant Neoplasm in the Soft Tissues;   Metastatic Urothelial Carcinoma of the Renal Pelvis and Ureter;   Recurrent Bladder Carcinoma;   Recurrent Prostate Carcinoma;   Recurrent Urothelial Carcinoma of the Renal Pelvis and Ureter;   Stage IV Bladder Cancer;   Stage IV Bladder Urothelial Carcinoma;   Stage IV Prostate Cancer
  Interventions:   Other: Cytology Specimen Collection Procedure;   Other: Laboratory Biomarker Analysis
  Sponsors:   University of Washington;   National Cancer Institute (NCI)
  Recruiting
• Individualizing Incentives for Alcohol in the Severely Mentally Ill

  NCT03481049

  Conditions:   Schizophrenia;   Bipolar Disorder;   Major Depressive Disorder;   Alcohol Dependence
  Interventions:   Behavioral: Usual CM;   Behavioral: High-Magnitude CM;   Behavioral: Shaping CM
  Sponsors:   Washington State University;   National Institute on Alcohol Abuse and Alcoholism (NIAAA)
  Recruiting
• Nozin in Preventing Respiratory Viral Infections in Patients Undergoing Stem Cell Transplant, PREV-NOSE STUDY

  NCT04060849

  Conditions:   Viral Upper Respiratory Tract Infection;   Allogeneic Bone Marrow Transplantation Recipient
  Interventions:   Drug: Nozin;   Other: Best Practice
  Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI);   Global Life Technologies Corp.
  Recruiting
• In Vivo Study to Assess the Recovery and Survival of Radiolabeled Autologous INTERCEPT Apheresis Platelet Components Suspended in 100% Plasma Stored for up to 7 Days

  NCT04022889

  Condition:   Healthy
  Intervention:   Device: INTERCEPT Treated Platelets
  Sponsor:   Cerus Corporation
  Recruiting
• CISTO: Comparison of Intravesical Therapy and Surgery as Treatment Options for Bladder Cancer

  NCT03933826

  Conditions:   Bladder Cancer;   Cancer of the Bladder, Recurrent;   Non-muscle Invasive Bladder Cancer
  Intervention:  
  Sponsors:   University of Washington;   Patient-Centered Outcomes Research Institute
  Recruiting
• TR1801-ADC in Patients With Tumors That Express c-Met

  NCT03859752

  Condition:   Unspecified Adult Solid Tumor, Protocol Specific
  Intervention:   Biological: TR1801-ADC
  Sponsors:   Tanabe Research Laboratories USA Inc;   Open Innovation Partners
  Recruiting
• Cognitive Behavioral Therapy, Modafinil, or Both for Multiple Sclerosis Fatigue

  NCT03621761

  Condition:   Multiple Sclerosis
  Interventions:   Behavioral: Telephone-based Cognitive Behavioral Therapy;   Drug: Modafinil
  Sponsors:   University of Michigan;   University of Washington;   Patient-Centered Outcomes Research Institute;   National Multiple Sclerosis Society
  Recruiting
• Trial of Azithromycin vs. Doxycycline for the Treatment of Rectal Chlamydia in MSM

  NCT03608774

  Condition:   Anal Chlamydia Infection
  Interventions:   Drug: Azithromycin;   Drug: Doxycycline;   Other: Placebo
  Sponsor:   National Institute of Allergy and Infectious Diseases (NIAID)
  Recruiting
• Study of Nivolumab, Cabiralizumab, and Stereotactic Body Radiotherapy (SBRT) for Locally Advanced Unresectable Pancreatic Cancer

  NCT03599362

  Condition:   Pancreatic Cancer
  Interventions:   Drug: Nivolumab + Cabiralizumab;   Radiation: Stereotactic Body Radiotherapy (SBRT)
  Sponsor:   NYU Langone Health
  Recruiting
• Alcohol Research Consortium in HIV-Intervention Research Arm

  NCT02938377

  Conditions:   HIV Positive;   Alcohol Use
  Interventions:   Behavioral: Computerized Brief Intervention (CBI);   Behavioral: CBT4CBT;   Drug: Recommendation and Counseling for Alcohol Pharmacotherapy
  Sponsor:   University of Alabama at Birmingham
  Recruiting
• ESTIA: Computerized Intervention Targeting Cognitive Control Deficits in Depressed Adults

  NCT02891564

  Condition:   Major Depression
  Interventions:   Behavioral: Band Together;   Other: Control Mobile 3D video game
  Sponsors:   University of Washington;   Weill Medical College of Cornell University;   University of California, San Francisco
  Recruiting
• Apalutamide in Treating Patients With Prostate Cancer Who Are in Active Surveillance

  NCT02721979

  Conditions:   Prostate Adenocarcinoma;   Testosterone Greater Than or Equal to 150 ng/dL
  Interventions:   Drug: Apalutamide;   Other: Laboratory Biomarker Analysis;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration
  Sponsors:   University of Washington;   Janssen Scientific Affairs, LLC;   National Cancer Institute (NCI)
  Recruiting
• Advancing Symptom Alleviation With Palliative Treatment

  NCT02713347

  Conditions:   Heart Failure;   Pulmonary Disease, Chronic Obstructive;   Emphysema;   Pulmonary Fibrosis, Interstitial Lung Disease
  Intervention:   Behavioral: ADAPT Intervention
  Sponsor:   VA Office of Research and Development
  Recruiting
• Afatinib Dimaleate and Capecitabine in Treating Patients With Advanced Refractory Solid Tumors, Pancreatic Cancer or Biliary Cancer

  NCT02451553

  Conditions:   Advanced Malignant Solid Neoplasm;   Bile Duct Carcinoma;   Recurrent Malignant Solid Neoplasm;   Recurrent Pancreatic Carcinoma;   Stage III Pancreatic Cancer AJCC v6 and v7;   Stage IVA Pancreatic Cancer;   Stage IVB Pancreatic Cancer
  Interventions:   Drug: Afatinib Dimaleate;   Drug: Capecitabine;   Other: Laboratory Biomarker Analysis
  Sponsors:   University of Washington;   National Cancer Institute (NCI)
  Recruiting
• Facilitating Communication Study

  NCT03721952

  Conditions:   Chronic Disease;   Neoplasm Metastasis;   Lung Neoplasm;   Pulmonary Disease, Chronic Obstructive;   Heart Failure, Congestive;   Liver Cirrhosis;   Kidney Failure, Chronic;   Multiple Organ Failure;   Health Care Quality, Access, and Evaluation;   Intensive Care Units;   Palliative Care, Health Services;   Palliative Care, Patient Care;   Lung Diseases, Interstitial
  Intervention:   Behavioral: Facilitator-Based Intervention
  Sponsor:   University of Washington
  Recruiting
• Rituximab Hyaluronidase in Combination With Chemotherapy in Treating Aggressive B-cell Lymphoma in Uganda

  NCT03864419

  Conditions:   Burkitt Lymphoma;   KSHV-associated Multicentric Castleman Disease;   Diffuse Large B-Cell Lymphoma
  Interventions:   Biological: Rituximab or Rituximab Hyaluronidase Human;   Drug: Cyclophosphamide;   Drug: Vincristine;   Drug: Methotrexate;   Drug: Doxorubicin;   Drug: Doxorubicin Hydrochloride;   Drug: Prednisone;   Drug: Etoposide
  Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI)
  Recruiting
• Yeego! Healthy Eating & Gardening

  NCT03778021

  Conditions:   Dietary Habits;   Health Behavior;   Eating Behavior
  Interventions:   Behavioral: Behavioral Gardening Exposure;   Behavioral: Healthy Eating and Gardening Curriculum;   Behavioral: Family Workshops
  Sponsor:   Fred Hutchinson Cancer Research Center
  Recruiting
• Fractionated Gemtuzumab Ozogamicin in Treating Measurable Residual Disease in Participants With Acute Myeloid Leukemia

  NCT03737955

  Conditions:   Acute Myeloid Leukemia;   CD33 Positive;   Minimal Residual Disease
  Interventions:   Drug: Gemtuzumab Ozogamicin;   Other: Quality-of-Life Assessment
  Sponsors:   University of Washington;   National Cancer Institute (NCI)
  Recruiting
• Understanding Prosthetic Needs and Outcomes in Women Veterans With Amputation

  NCT03733054

  Condition:   Amputation
  Intervention:  
  Sponsor:   VA Office of Research and Development
  Recruiting
• Mechanisms of Metabolic and Hormone Action on Plaque Formation in Brain and Carotid Vessels in Prostate Adenocarcinoma

  NCT03718338

  Condition:   Prostate Adenocarcinoma
  Interventions:   Procedure: Evaluation;   Other: Quality-of-Life Assessment
  Sponsors:   University of Washington;   National Cancer Institute (NCI)
  Recruiting
• Discontinuation or Continuation of Immunosuppressive Therapy in Participants With Chronic Graft Versus Host Disease

  NCT03483675

  Conditions:   Chronic Graft Versus Host Disease;   Hematopoietic Cell Transplantation Recipient
  Interventions:   Biological: Immunosuppressive Therapy;   Other: Survey Administration
  Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI)
  Recruiting
• Comparison of Triple GVHD Prophylaxis Regimens for Nonmyeloablative or Reduced Intensity Conditioning Unrelated Mobilized Blood Cell Transplantation

  NCT03246906

  Conditions:   Acute Lymphoblastic Leukemia;   Acute Myeloid Leukemia;   Aggressive Non-Hodgkin Lymphoma;   Chronic Lymphocytic Leukemia;   Diffuse Large B-Cell Lymphoma;   Hematopoietic Cell Transplant Recipient;   Loss of Chromosome 17p;   Mantle Cell Lymphoma;   Myelodysplastic Syndrome;   Myelodysplastic/Myeloproliferative Neoplasm;   Prolymphocytic Leukemia;   Recurrent Chronic Lymphocytic Leukemia;   Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Recurrent Hodgkin Lymphoma;   Recurrent Plasma Cell Myeloma;   Recurrent Small Lymphocytic Lymphoma;   Recurrent Waldenstrom Macroglobulinemia
  Interventions:   Procedure: Allogeneic Hematopoietic Stem Cell Transplantation;   Drug: Cyclophosphamide;   Drug: Cyclosporine;   Drug: Mycophenolate Mofetil;   Drug: Sirolimus
  Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI)
  Recruiting
• Veteran Peer Coaches Optimizing and Advancing Cardiac Health

  NCT02697422

  Conditions:   Cardiovascular Disease (CVD);   Hypertension;   Hyperlipemia;   Obesity
  Intervention:   Other: Community-based peer health coach intervention
  Sponsor:   VA Office of Research and Development
  Recruiting
• Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies

  NCT01028716

  Conditions:   Acute Biphenotypic Leukemia;   Acute Erythroid Leukemia in Remission;   Acute Leukemia in Remission;   Acute Lymphoblastic Leukemia in Remission;   Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome;   Acute Myeloid Leukemia in Remission;   Acute Myeloid Leukemia With FLT3/ITD Mutation;   Acute Myeloid Leukemia With Inv(3) (q21.3;q26.2); GATA2, MECOM;   Acute Myeloid Leukemia With Multilineage Dysplasia;   Acute Myeloid Leukemia With t(6;9) (p23;q34.1); DEK-NUP214;   Acute Undifferentiated Leukemia;   Adult Acute Lymphoblastic Leukemia in Complete Remission;   B Acute Lymphoblastic Leukemia With t(1;19)(q23;p13.3); E2A-PBX1 (TCF3-PBX1);   B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1;   Burkitt Lymphoma;   Childhood Acute Lymphoblastic Leukemia in Complete Remission;   DS Stage II Plasma Cell Myeloma;   DS Stage III Plasma Cell Myeloma;   Myelodysplastic Syndrome;   Recurrent Anaplastic Large Cell Lymphoma;   Blasts Under 5 Percent of Bone Marrow Nucleated Cells;   Recurrent Follicular Lymphoma;   Recurrent Hodgkin Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Plasma Cell Myeloma;   Refractory Plasma Cell Myeloma;   Secondary Acute Myeloid Leukemia;   T Lymphoblastic Lymphoma;   Hematopoietic Cell Transplant Recipient
  Interventions:   Drug: Cyclophosphamide;   Biological: Filgrastim;   Drug: Fludarabine Phosphate;   Procedure: Laboratory Biomarker Analysis;   Drug: Mycophenolate Mofetil;   Procedure: Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation;   Procedure: Peripheral Blood Stem Cell Transplantation;   Drug: Tacrolimus;   Radiation: Total-Body Irradiation;   Drug: Fludarabine
  Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI)
  Recruiting
• The GBA Multimodal Study in Parkinson's Disease

  NCT04101968

  Conditions:   Parkinson Disease;   GBA Gene Mutation;   Gaucher Disease
  Interventions:   Diagnostic Test: PET scan;   Diagnostic Test: neuroQWERTY
  Sponsors:   Pacific Parkinson's Research Centre;   University of British Columbia;   University of Washington;   Oregon Health and Science University;   Simon Fraser University;   Michael J. Fox Foundation for Parkinson's Research;   Silverstein Foundation;   Weston Brain Institute
  Recruiting
• Break Wave(TM) Extracorporeal Lithotripter First-in-Human Study

  NCT03811171

  Conditions:   Renal Calculi;   Urinary Calculi
  Intervention:   Device: Break Wave extracorporeal lithotripsy
  Sponsor:   SonoMotion
  Recruiting
• Diet Intervention for Hypertension: Adaptation and Dissemination to Native Communities

  NCT02796313

  Condition:   Hypertension
  Interventions:   Behavioral: DASH Groceries + Weekly Sessions;   Behavioral: Groceries + Brochure
  Sponsors:   Washington State University;   Oklahoma State University
  Recruiting
• Glasdegib for Chronic Graft-Versus-Host Disease

  NCT04111497

  Conditions:   Chronic Graft Versus Host Disease;   Fasciitis;   Sclerosis
  Intervention:   Drug: Glasdegib
  Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI);   Pfizer
  Recruiting
• Preventing Levodopa Induced Dyskinesia in Parkinson's Disease With HMG-CoA Reductase Inhibitors

  NCT04064294

  Conditions:   Parkinson Disease;   Dyskinesia, Drug-Induced
  Intervention:   Drug: Intravenous Infusion
  Sponsors:   VA Office of Research and Development;   Oregon Health and Science University
  Recruiting
• Optimizing a Mobile Mindfulness Intervention for ICU Survivors

  NCT04038567

  Condition:   Cardiorespiratory Failure
  Intervention:   Behavioral: Mobile mindfulness-based training
  Sponsors:   Duke University;   University of Washington;   University of Colorado, Denver;   National Center for Complementary and Integrative Health (NCCIH)
  Recruiting
• A Study to Evaluate the Safety, Tolerability of DN1508052-01 in Advanced Solid Tumors

  NCT03934359

  Condition:   Advanced Solid Tumors
  Intervention:   Drug: DN1508052-01
  Sponsor:   Shanghai De Novo Pharmatech Co., Ltd.
  Recruiting
• Linaclotide in Treating Patients With Stages 0-3 Colorectal Cancer

  NCT03796884

  Condition:   Colorectal Adenoma
  Interventions:   Drug: Linaclotide;   Other: Placebo
  Sponsors:   Sidney Kimmel Cancer Center at Thomas Jefferson University;   United States Department of Defense
  Recruiting
• A Test-Drive Strategy for the Prescription of Prosthetic Feet for People With Leg Amputations

  NCT03651830

  Condition:   Amputation
  Interventions:   Device: Prosthetic Foot Emulator;   Device: Commercially available prosthetic feet
  Sponsors:   Seattle Institute for Biomedical and Clinical Research;   VA Puget Sound Health Care System;   Minneapolis Veterans Affairs Medical Center;   Brooke Army Medical Center;   Stanford University;   University of Washington
  Recruiting
• Inpatient Palliative Care for Patients Undergoing Hematopoietic Stem Cell Transplantation

  NCT03641378

  Condition:   Stem Cell Transplant
  Interventions:   Other: Palliative Care Intervention;   Other: Standard Transplant Care
  Sponsors:   Massachusetts General Hospital;   National Institutes of Health (NIH);   National Cancer Institute (NCI)
  Recruiting
• Promoting Smoking Cessation in Lung Cancer Screening Through Proactive Treatment

  NCT03612804

  Conditions:   Smoking Reduction;   Tobacco Use;   Tobacco Smoking;   Tomography;   Lung Diseases;   Lung Neoplasms
  Interventions:   Behavioral: Unsigned note to provider about cessation medication prescription;   Behavioral: Proactive Telephone Counseling from VA Quitline
  Sponsors:   VA Office of Research and Development;   Fred Hutchinson Cancer Research Center
  Recruiting
• Spinal Manipulation and Patient Self-Management for Preventing Acute to Chronic Back Pain

  NCT03581123

  Conditions:   Acute Pain;   Low Back Pain, Mechanical
  Interventions:   Behavioral: Supported-Self Management (SSM);   Other: Spinal Manipulation Therapy (SMT);   Combination Product: SMT + SSM;   Drug: Standard Medical Care (SMC)
  Sponsors:   University of Minnesota;   University of Pittsburgh;   University of Washington;   University of North Texas Health Science Center;   Oregon Health and Science University;   Duke University
  Recruiting
• CPX-351 (Vyxeos™) for Transplant Eligible, Higher Risk Patients With Myelodysplastic Syndrome

  NCT03572764

  Condition:   Myelodysplastic Syndromes
  Interventions:   Drug: CPX-351;   Procedure: Research skin biopsy;   Procedure: Research blood draw;   Procedure: Research bone marrow aspirate
  Sponsors:   Washington University School of Medicine;   Jazz Pharmaceuticals
  Recruiting
• Pembrolizumab Plus Y90 Radioembolization in HCC Subjects

  NCT03099564

  Condition:   Hepatocellular Carcinoma
  Interventions:   Drug: Pembrolizumab;   Device: Y90 radioembolization
  Sponsors:   Autumn McRee, MD;   Merck Sharp & Dohme Corp.;   Hoosier Cancer Research Network
  Recruiting
• Precise Local Injection of Anti-cancer Drugs Using Presage's CIVO™ Device in Soft Tissue Sarcoma

  NCT03056599

  Condition:   Soft Tissue Sarcoma Adult
  Interventions:   Drug: Multiple drug microinjection;   Device: CIVO device
  Sponsors:   Presage Biosciences;   Fred Hutchinson Cancer Research Center;   University of Washington;   Northwell Health;   Oregon Health and Science University
  Recruiting
• Alpers Huttenlocher Natural History Study

  NCT03034512

  Condition:   Alpers Huttenlocher Syndrome
  Intervention:  
  Sponsors:   Columbia University;   Seattle Children's Hospital;   National Institute of Neurological Disorders and Stroke (NINDS)
  Recruiting
• Docetaxel and Carboplatin for Patients With mCRPC and DNA-Repair Deficiencies

  NCT02985021

  Conditions:   Hormone-Resistant Prostate Cancer;   Metastatic Prostate Carcinoma;   Recurrent Prostate Carcinoma;   Stage IV Prostate Cancer
  Interventions:   Drug: Carboplatin;   Drug: Docetaxel
  Sponsors:   Seattle Institute for Biomedical and Clinical Research;   Prostate Cancer Foundation;   VA Puget Sound Health Care System
  Recruiting
• Study of Immunotherapy in Combination With Ublituximab and Umbralisib in Patients With Relapsed-refractory CLL or Richter's Transformation

  NCT02535286

  Conditions:   Chronic Lymphocytic Leukemia;   Richter Syndrome
  Interventions:   Drug: Umbralisib;   Biological: ublituximab;   Biological: TG-1501
  Sponsors:   TG Therapeutics, Inc.;   Memorial Sloan Kettering Cancer Center
  Recruiting
• Trial Comparing Relapse Rates Between Standard Ureteroscopic Removal Of Ureteral Stone And Standard Removal With Additional Ureterorenic Clearing Of Non-Symptomatic Stones In The Kidney

  NCT02210650

  Condition:   Ureteral Stones
  Interventions:   Procedure: Ureteral stone removal;   Procedure: Asymptomatic kidney stones and ureteral stone removed
  Sponsors:   Indiana Kidney Stone Institute;   University of Washington Medical Center Department of Urology (Seattle, WA);   VA Puget Sound Health Care System
  Recruiting
• Chemotherapy in Treating Patients With Myelodysplastic Syndrome Before Donor Stem Cell Transplant

  NCT01812252

  Conditions:   Chronic Myelomonocytic Leukemia;   de Novo Myelodysplastic Syndrome;   Myelodysplastic Syndrome;   Secondary Myelodysplastic Syndrome
  Interventions:   Drug: Azacitidine;   Drug: Decitabine;   Other: Quality-of-Life Assessment
  Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI)
  Recruiting
• Autologous Peripheral Blood Stem Cell Transplant for Neurologic Autoimmune Diseases

  NCT00716066

  Conditions:   Autoimmune Disease;   Neurologic Autoimmune Disease;   Autologous Transplant Autoimmune;   Multiple Sclerosis Transplant;   MS Stem Cell Transplant;   Multiple Sclerosis Stem Cell Transplant;   Stiff Person Syndrome;   HCT for Neurologic Autoimmune Disorders;   CIDP Transplant;   Myasthenia Gravis Transplant
  Interventions:   Biological: Anti-Thymocyte Globulin;   Procedure: Autologous Hematopoietic Stem Cell Transplantation;   Drug: Carmustine;   Drug: Cytarabine;   Drug: Etoposide;   Other: Laboratory Biomarker Analysis;   Drug: Melphalan;   Procedure: Peripheral Blood Stem Cell Transplantation;   Drug: Prednisone;   Procedure: Syngeneic Bone Marrow Transplantation
  Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI)
  Recruiting
• Communication During Hospitalization About Resuscitation Trial

  NCT02984124

  Conditions:   Severe Life-limiting COPD;   Severe Life-limiting Heart Failure;   Severe Life-limiting Cirrhosis;   Severe Life-limiting Malignancy;   Severe Functional Impairment
  Interventions:   Behavioral: Informed Assent Discussion;   Behavioral: Usual Care with Attention Control
  Sponsors:   University of Vermont;   University of Washington;   Medical University of South Carolina;   University of California, San Francisco
  Recruiting
• A Phase 1 Study to Evaluate SNDX- 6352 in Subjects With Active cGVHD

  NCT03604692

  Condition:   Chronic Graft-versus-host-disease
  Intervention:   Drug: SNDX-6352
  Sponsor:   Syndax Pharmaceuticals
  Recruiting
• Neurocognition in Congenital Central Hypoventilation Syndrome (CCHS)

  NCT03568669

  Conditions:   Congenital Central Hypoventilation Syndrome;   Congenital Central Hypoventilation;   CCHS;   CCHS With Hirschsprung Disease;   CCHS With Neural Crest Tumor;   CCHS With Neuroblastoma
  Intervention:   Other: NIH Toolbox Cognition Battery
  Sponsors:   Debra Weese-Mayer;   Ann & Robert H Lurie Children's Hospital of Chicago;   Seattle Children's Hospital;   Children's Hospital Los Angeles
  Recruiting
• Initial and Chronic Methicillin Resistant Staphylococcus Aureus (MRSA) Infection in Cystic Fibrosis (CF)

  NCT02684422

  Conditions:   Methicillin-Resistant Staphylococcus Aureus;   Cystic Fibrosis
  Intervention:   Other: Intervention N/A. Observational study
  Sponsor:   University of North Carolina, Chapel Hill
  Recruiting
• A Pilot Study of Oraxol in Subjects With Cutaneous Angiosarcoma

  NCT03544567

  Condition:   Angiosarcoma of Skin
  Intervention:   Drug: Oraxol
  Sponsor:   Athenex, Inc.
  Recruiting
• HSCT for Patients With Fanconi Anemia Using Risk-Adjusted Chemotherapy

  NCT02143830

  Conditions:   Fanconi Anemia;   Severe Marrow Failure;   Myelodysplastic Syndrome (MDS);   Acute Myelogenous Leukemia (AML)
  Interventions:   Drug: Busulfan;   Drug: Cyclophosphamide;   Drug: Fludarabine;   Drug: rabbit ATG;   Drug: G-CSF;   Biological: Peripheral blood stem cell
  Sponsors:   Children's Hospital Medical Center, Cincinnati;   Memorial Sloan Kettering Cancer Center;   Fred Hutchinson Cancer Research Center
  Recruiting
• Study of Ruxolitinib in Sclerotic Chronic Graft-Versus-Host Disease After Failure of Systemic Glucocorticoids

  NCT03616184

  Condition:   Graft-versus-host-disease (GVHD)
  Intervention:   Drug: Ruxolitinib
  Sponsor:   University of Nebraska
  Recruiting
• A Safety Study of SEA-BCMA in Patients With Multiple Myeloma

  NCT03582033

  Condition:   Multiple Myeloma
  Intervention:   Drug: SEA-BCMA
  Sponsor:   Seattle Genetics, Inc.
  Recruiting
• A Study to Investigate the Safety, Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of TAK-573 in Participants With Refractory Multiple Myeloma (MM)

  NCT03215030

  Condition:   Multiple Myeloma
  Interventions:   Drug: TAK-573;   Drug: Dexamethasone
  Sponsor:   Millennium Pharmaceuticals, Inc.
  Recruiting
• High vs. Standard Dose Flu Vaccine in Adult Stem Cell Transplant Recipients

  NCT03179761

  Condition:   Hematopoietic Cell Transplantation
  Interventions:   Biological: Quadrivalent Inactivated Influenza Vaccine;   Other: Laboratory Biomarker Analysis;   Biological: Trivalent Influenza Vaccine
  Sponsor:   Vanderbilt-Ingram Cancer Center
  Recruiting
• Opioid Use Disorder in the Emergency Department: CTN 0069

  NCT03023930

  Condition:   Opioid Use Disorder
  Interventions:   Other: Standard Dissemination Practice;   Other: Implementation Facilitation (IF)
  Sponsors:   Yale University;   National Institute on Drug Abuse (NIDA);   The Emmes Company, LLC
  Recruiting
• Nivolumab, Ifosfamide, Carboplatin, and Etoposide as Second-Line Therapy in Treating Patients With Refractory or Relapsed Hodgkin Lymphoma

  NCT03016871

  Conditions:   Recurrent Hodgkin Lymphoma;   Refractory Hodgkin Lymphoma
  Interventions:   Drug: Carboplatin;   Drug: Etoposide;   Drug: Ifosfamide;   Other: Laboratory Biomarker Analysis;   Biological: Nivolumab
  Sponsors:   City of Hope Medical Center;   National Cancer Institute (NCI)
  Recruiting
• Pembrolizumab in Refractory Metastatic Anal Cancer

  NCT02919969

  Condition:   Anal Cancer
  Intervention:   Drug: Pembrolizumab
  Sponsors:   Dana-Farber Cancer Institute;   Merck Sharp & Dohme Corp.
  Recruiting
• Testing The Addition of a New Anti-cancer Drug, Venetoclax, to the Usual Treatment (Ibrutinib and Obinutuzumab) in Untreated, Older Patients With Chronic Lymphocytic Leukemia

  NCT03737981

  Condition:   Chronic Lymphocytic Leukemia
  Interventions:   Drug: Ibrutinib;   Biological: Obinutuzumab;   Other: Observation;   Drug: Venetoclax
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• Palbociclib and Letrozole or Fulvestrant in Treating Patients With Estrogen Receptor Positive, HER2 Negative Metastatic Breast Cancer

  NCT03633331

  Conditions:   Estrogen Receptor-positive Breast Cancer;   HER2/Neu Negative;   Stage IV Breast Cancer AJCC v6 and v7
  Interventions:   Drug: Palbociclib;   Drug: Letrozole;   Drug: Fulvestrant;   Other: Questionnaire Administration;   Other: Quality-of-Life Assessment
  Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI)
  Recruiting
• A Study of Bendamustine and Rituximab Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated Mantle Cell Lymphoma

  NCT02972840

  Condition:   Lymphoma, Mantle Cell
  Interventions:   Drug: Acalabrutinib in combination with bendamustine and rituximab;   Drug: Placebo in combination with bendamustine and rituximab
  Sponsor:   Acerta Pharma BV
  Recruiting
• Diffusion MRI-1 Imaging Database

  NCT03775694

  Conditions:   Epilepsy;   Tumor;   Healthy;   Other
  Intervention:   Device: dMRI Scan
  Sponsor:   Medtronic Surgical Technologies
  Recruiting
• Effects of Emicizumab vs. Factor VIII Prophylaxis on Joint and Bone Health in Severe Hemophilia A

  NCT04131036

  Condition:   Hemophilia A
  Intervention:   Other: assessment of joint health and bone density
  Sponsors:   Bloodworks;   Genentech, Inc.
  Recruiting
• Dried Blood Spot Testing of CMV Detection in HCT Recipients

  NCT03910478

  Condition:   Cytomegalovirus Infection
  Interventions:   Device: DBS Self-Collection Kit;   Other: Standard Control Strategy
  Sponsor:   National Institute of Allergy and Infectious Diseases (NIAID)
  Recruiting
• Brain Oxygen Optimization in Severe TBI, Phase 3

  NCT03754114

  Condition:   Brain Injuries, Traumatic
  Interventions:   Other: ICP + PbtO2 guided management strategy;   Other: ICP guided management strategy
  Sponsors:   University of Michigan;   National Institute of Neurological Disorders and Stroke (NINDS);   University of Washington;   University of Pennsylvania;   University of Pittsburgh;   Medical University of South Carolina
  Recruiting
• Surgery in Treating Patients With Early Stage Anal Canal or Perianal Cancer and HIV Infection

  NCT02437851

  Conditions:   Anal Squamous Cell Carcinoma;   HIV Infection;   Stage 0 Anal Canal Cancer;   Stage I Anal Canal Cancer
  Intervention:   Procedure: Therapeutic Conventional Surgery
  Sponsors:   AIDS Malignancy Consortium;   National Cancer Institute (NCI);   The Emmes Company, LLC;   AIDS and Cancer Specimen Resource;   University of Arkansas
  Recruiting
• Evaluating the Efficacy and Safety of Transitioning Patients From Natalizumab to Ocrelizumab

  NCT03157830

  Condition:   Relapsing Remitting Multiple Sclerosis
  Intervention:  
  Sponsors:   Providence Health & Services;   Genentech, Inc.
  Recruiting
• RESPOND TO PREVENT: Stepwise Pharmacy Naloxone Study

  NCT03545321

  Conditions:   Pharmacies;   Opioid Use;   Patient Safety
  Intervention:   Behavioral: MOON+
  Sponsors:   Boston Medical Center;   Comagine Health;   Oregon Health and Science University;   University of Rhode Island;   University of Washington;   National Institute on Drug Abuse (NIDA)
  Recruiting
• SEL24/MEN1703 in Patients With Acute Myeloid Leukemia

  NCT03008187

  Condition:   Acute Myeloid Leukemia
  Intervention:   Drug: SEL24/MEN1703
  Sponsors:   Menarini Group;   Medpace, Inc.;   Theradex
  Recruiting
• Use of an Experimental Drug, CC-115, With Enzalutamide in Men With Castration-Resistant Prostate Cancer

  NCT02833883

  Conditions:   Prostate Cancer;   Castration Resistant Prostate Cancer
  Interventions:   Drug: Enzalutamide;   Drug: CC-115
  Sponsors:   Memorial Sloan Kettering Cancer Center;   Celgene Corporation
  Recruiting
• Clinical Factors and Gene Expression Analysis for Prognosis in Tissue Samples From Patients With AIDS-Related Primary Effusion Lymphoma

  NCT02823327

  Condition:   AIDS-Related Primary Effusion Lymphoma
  Interventions:   Genetic: Laboratory Biomarker Analysis;   Other: Medical Chart Review
  Sponsors:   AIDS Malignancy Consortium;   National Cancer Institute (NCI);   University of California, San Diego;   University of Arkansas
  Recruiting
• Vaccine Therapy in Reducing the Frequency of Cytomegalovirus Events in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant

  NCT02396134

  Conditions:   Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Adult Acute Lymphoblastic Leukemia in Remission;   Adult Acute Myeloid Leukemia in Remission;   Adult Hodgkin Lymphoma;   Adult Non-Hodgkin Lymphoma;   Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Cytomegaloviral Infection;   Hematopoietic and Lymphoid Cell Neoplasm;   HLA-A*0201 Positive Cells Present;   Myelodysplastic Syndrome;   Adult Lymphoblastic Lymphoma;   Chronic Lymphocytic Leukemia;   Myelofibrosis;   Myeloproliferative Neoplasm
  Interventions:   Biological: CMVpp65-A*0201 peptide vaccine;   Other: Placebo;   Other: Laboratory Biomarker Analysis
  Sponsors:   City of Hope Medical Center;   National Cancer Institute (NCI)
  Recruiting
• Letrozole With or Without Paclitaxel and Carboplatin in Treating Patients With Stage II-IV Ovarian or Primary Peritoneal Cancer

  NCT04095364

  Conditions:   Low Grade Ovarian Serous Adenocarcinoma;   Primary Peritoneal Low Grade Serous Adenocarcinoma;   Stage II Ovarian Cancer AJCC v8;   Stage IIA Ovarian Cancer AJCC v8;   Stage IIB Ovarian Cancer AJCC v8;   Stage III Ovarian Cancer AJCC v8;   Stage IIIA Ovarian Cancer AJCC v8;   Stage IIIA1 Ovarian Cancer AJCC v8;   Stage IIIA2 Ovarian Cancer AJCC v8;   Stage IIIB Ovarian Cancer AJCC v8;   Stage IIIC Ovarian Cancer AJCC v8;   Stage IV Ovarian Cancer AJCC v8;   Stage IVA Ovarian Cancer AJCC v8;   Stage IVB Ovarian Cancer AJCC v8
  Interventions:   Drug: Carboplatin;   Drug: Letrozole;   Drug: Paclitaxel
  Sponsors:   NRG Oncology;   National Cancer Institute (NCI)
  Recruiting
• Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma

  NCT03937635

  Condition:   Smoldering Plasma Cell Myeloma
  Interventions:   Biological: Daratumumab;   Drug: Dexamethasone;   Drug: Lenalidomide;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration
  Sponsors:   ECOG-ACRIN Cancer Research Group;   National Cancer Institute (NCI)
  Recruiting
• Ibrutinib and Obinutuzumab With or Without Venetoclax in Treating Patients With Chronic Lymphocytic Leukemia

  NCT03701282

  Conditions:   Chronic Lymphocytic Leukemia;   Small Lymphocytic Lymphoma
  Interventions:   Drug: Ibrutinib;   Biological: Obinutuzumab;   Other: Quality-of-Life Assessment;   Drug: Venetoclax
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• Carboplatin and Paclitaxel With or Without Ramucirumab in Treating Patients With Locally Advanced, Recurrent, or Metastatic Thymic Cancer That Cannot Be Removed by Surgery

  NCT03694002

  Conditions:   Locally Advanced Thymic Carcinoma;   Metastatic Thymic Carcinoma;   Recurrent Thymic Carcinoma;   Unresectable Thymic Carcinoma
  Interventions:   Drug: Carboplatin;   Drug: Paclitaxel;   Biological: Ramucirumab
  Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
  Recruiting
• Ruxolitinib Phosphate and Dasatinib or Nilotinib in Treating Patients With Chronic Myeloid Leukemia

  NCT03654768

  Condition:   Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
  Interventions:   Drug: Dasatinib;   Other: Laboratory Biomarker Analysis;   Drug: Nilotinib;   Drug: Ruxolitinib Phosphate
  Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
  Recruiting
• S1501 Carvedilol in Preventing Cardiac Toxicity in Patients With Metastatic HER-2-Positive Breast Cancer

  NCT03418961

  Conditions:   Cardiotoxicity;   HER2/Neu Positive;   Metastatic Malignant Neoplasm in the Brain;   Recurrent Breast Carcinoma;   Stage IV Breast Cancer AJCC v6 and v7
  Interventions:   Drug: Carvedilol;   Other: Laboratory Biomarker Analysis;   Other: Patient Observation
  Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
  Recruiting
• Pembrolizumab in Treating Patients With Locally Advanced Bladder Cancer

  NCT03244384

  Conditions:   Stage II Bladder Urothelial Carcinoma AJCC v6 and v7;   Stage III Bladder Urothelial Carcinoma AJCC v6 and v7
  Interventions:   Other: Clinical Observation;   Other: Laboratory Biomarker Analysis;   Biological: Pembrolizumab;   Other: Pharmacological Study;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer

  NCT03233711

  Conditions:   Anal Basaloid Carcinoma;   Anal Canal Cloacogenic Carcinoma;   Anal Margin Squamous Cell Carcinoma;   Stage IIB Anal Cancer AJCC v8;   Stage IIIA Anal Cancer AJCC v8;   Stage IIIB Anal Cancer AJCC v8;   Stage IIIC Anal Cancer AJCC v8
  Interventions:   Biological: Nivolumab;   Other: Patient Observation
  Sponsors:   National Cancer Institute (NCI);   Canadian Cancer Trials Group
  Recruiting
• Aspirin in Preventing Recurrence of Cancer in Patients With HER2 Negative Stage II-III Breast Cancer After Chemotherapy, Surgery, and/or Radiation Therapy

  NCT02927249

  Condition:   Node Positive HER2 Negative Breast Cancer
  Interventions:   Other: Placebo;   Drug: Aspirin
  Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI);   United States Department of Defense;   Bayer;   Canadian Cancer Trials Group
  Recruiting
• Combination Chemotherapy With or Without Atezolizumab in Treating Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair

  NCT02912559

  Conditions:   Colon Adenocarcinoma;   DNA Repair Disorder;   Lynch Syndrome;   Stage III Colon Cancer AJCC v7;   Stage IIIA Colon Cancer AJCC v7;   Stage IIIB Colon Cancer AJCC v7;   Stage IIIC Colon Cancer AJCC v7
  Interventions:   Drug: Atezolizumab;   Drug: Fluorouracil;   Other: Laboratory Biomarker Analysis;   Drug: Leucovorin Calcium;   Drug: Oxaliplatin;   Other: Quality-of-Life Assessment
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• Breast Cancer WEight Loss Study (BWEL Study)

  NCT02750826

  Condition:   Breast Carcinoma
  Interventions:   Other: Health Education Program;   Other: Weight Loss Intervention
  Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI);   Division of Cancer Control;   NIH Biomarker, Imaging and Quality of Life Studies Funding Program (BIQSFP);   Canadian Cancer Trials Group
  Recruiting
• Ramucirumab and Pembrolizumab Versus Standard of Care in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Non-Match Treatment Trial)

  NCT03971474

  Conditions:   Recurrent Lung Non-Small Cell Carcinoma;   Stage IV Lung Cancer AJCC v8;   Stage IVA Lung Cancer AJCC v8;   Stage IVB Lung Cancer AJCC v8
  Interventions:   Drug: Docetaxel;   Drug: Gemcitabine;   Drug: Gemcitabine Hydrochloride;   Biological: Pembrolizumab;   Drug: Pemetrexed;   Drug: Pemetrexed Disodium;   Biological: Ramucirumab
  Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
  Recruiting
• Ipilimumab With or Without Nivolumab in Treating Patients With Melanoma That Is Stage IV or Stage III and Cannot Be Removed by Surgery

  NCT03033576

  Conditions:   Advanced Melanoma;   Melanoma of Unknown Primary;   Mucosal Melanoma;   Refractory Melanoma;   Stage III Cutaneous Melanoma AJCC v7;   Stage IIIA Cutaneous Melanoma AJCC v7;   Stage IIIB Cutaneous Melanoma AJCC v7;   Stage IIIC Cutaneous Melanoma AJCC v7;   Stage IV Cutaneous Melanoma AJCC v6 and v7;   Unresectable Cutaneous Melanoma;   Unresectable Melanoma
  Interventions:   Biological: Ipilimumab;   Biological: Nivolumab
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• Firstline Pembrolizumab Alone or in Combination With Pemetrexed and Carboplatin in Induction/Maintenance or Postprogression in Treating Patients With Stage IV Non-squamous Non-small Cell Lung Cancer

  NCT03793179

  Conditions:   Lung Non-Squamous Non-Small Cell Carcinoma;   Stage IIIB Lung Cancer AJCC v8;   Stage IIIC Lung Cancer AJCC v8;   Stage IVA Lung Cancer AJCC v8
  Interventions:   Drug: Carboplatin;   Biological: Pembrolizumab;   Drug: Pemetrexed
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• Gemcitabine Hydrochloride and Cisplatin With or Without Nab-Paclitaxel in Treating Patients With Newly Diagnosed Advanced Biliary Tract Cancers

  NCT03768414

  Conditions:   Stage III Distal Bile Duct Cancer AJCC v8;   Stage III Gallbladder Cancer AJCC v8;   Stage III Intrahepatic Cholangiocarcinoma AJCC v8;   Stage IIIA Distal Bile Duct Cancer AJCC v8;   Stage IIIA Gallbladder Cancer AJCC v8;   Stage IIIA Intrahepatic Cholangiocarcinoma AJCC v8;   Stage IIIB Distal Bile Duct Cancer AJCC v8;   Stage IIIB Gallbladder Cancer AJCC v8;   Stage IIIB Intrahepatic Cholangiocarcinoma AJCC v8;   Stage IV Distal Bile Duct Cancer AJCC v8;   Stage IV Gallbladder Cancer AJCC v8;   Stage IV Intrahepatic Cholangiocarcinoma AJCC v8;   Stage IVA Gallbladder Cancer AJCC v8;   Stage IVB Gallbladder Cancer AJCC v8;   Unresectable Extrahepatic Bile Duct Carcinoma;   Unresectable Gallbladder Carcinoma;   Unresectable Intrahepatic Cholangiocarcinoma
  Interventions:   Drug: Cisplatin;   Drug: Gemcitabine Hydrochloride;   Drug: Nab-paclitaxel
  Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
  Recruiting
• Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

  NCT02465060

  Conditions:   Advanced Malignant Solid Neoplasm;   Bladder Carcinoma;   Breast Carcinoma;   Cervical Carcinoma;   Colon Carcinoma;   Colorectal Carcinoma;   Endometrial Carcinoma;   Esophageal Carcinoma;   Gastric Carcinoma;   Glioma;   Head and Neck Carcinoma;   Kidney Carcinoma;   Liver and Intrahepatic Bile Duct Carcinoma;   Lung Carcinoma;   Lymphoma;   Malignant Uterine Neoplasm;   Melanoma;   Ovarian Carcinoma;   Pancreatic Carcinoma;   Plasma Cell Myeloma;   Prostate Carcinoma;   Rectal Carcinoma;   Recurrent Bladder Carcinoma;   Recurrent Breast Carcinoma;   Recurrent Cervical Carcinoma;   Recurrent Colon Carcinoma;   Recurrent Colorectal Carcinoma;   Recurrent Esophageal Carcinoma;   Recurrent Gastric Carcinoma;   Recurrent Glioma;   Recurrent Head and Neck Carcinoma;   Recurrent Liver Carcinoma;   Recurrent Lung Carcinoma;   Recurrent Lymphoma;   Recurrent Malignant Solid Neoplasm;   Recurrent Melanoma;   Recurrent Ovarian Carcinoma;   Recurrent Pancreatic Carcinoma;   Recurrent Plasma Cell Myeloma;   Recurrent Prostate Carcinoma;   Recurrent Rectal Carcinoma;   Recurrent Skin Carcinoma;   Recurrent Thyroid Gland Carcinoma;   Recurrent Uterine Corpus Carcinoma;   Refractory Lymphoma;   Refractory Malignant Solid Neoplasm;   Refractory Plasma Cell Myeloma;   Skin Carcinoma;   Thyroid Gland Carcinoma;   Uterine Corpus Cancer
  Interventions:   Drug: Adavosertib;   Drug: Afatinib;   Drug: Afatinib Dimaleate;   Drug: Binimetinib;   Drug: Capivasertib;   Drug: Copanlisib;   Drug: Copanlisib Hydrochloride;   Drug: Crizotinib;   Other: Cytology Specimen Collection Procedure;   Drug: Dabrafenib;   Drug: Dabrafenib Mesylate;   Drug: Dasatinib;   Drug: Defactinib;   Drug: Defactinib Hydrochloride;   Drug: Erdafitinib;   Drug: FGFR Inhibitor AZD4547;   Drug: Ipatasertib;   Other: Laboratory Biomarker Analysis;   Drug: Larotrectinib;   Drug: Larotrectinib Sulfate;   Biological: Nivolumab;   Drug: Osimertinib;   Drug: Palbociclib;   Biological: Pertuzumab;   Drug: PI3K-beta Inhibitor GSK2636771;   Drug: Sapanisertib;   Drug: Sunitinib Malate;   Drug: Taselisib;   Drug: Trametinib;   Biological: Trastuzumab;   Biological: Trastuzumab Emtansine;   Drug: Ulixertinib;   Drug: Vismodegib
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative Metastatic Breast Cancer

  NCT03723928

  Conditions:   Anatomic Stage IV Breast Cancer AJCC v8;   Estrogen Receptor Positive;   HER2/Neu Negative;   Progesterone Receptor Positive;   Prognostic Stage IV Breast Cancer AJCC v8;   Elevated CA15-3 or CEA or CA27-29
  Interventions:   Other: Usual care disease monitoring;   Other: Serum Tumor Marker directed disease monitoring;   Other: Quality-of-Life Assessment;   Other: Anxiety Questionnaire Administration
  Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
  Recruiting
• Pembrolizumab in Treating Patients With Stage III-IV High-Risk Melanoma Before and After Surgery

  NCT03698019

  Conditions:   Acral Lentiginous Melanoma;   Clinical Stage III Cutaneous Melanoma AJCC v8;   Clinical Stage IV Cutaneous Melanoma AJCC v8;   Mucosal Melanoma;   Pathologic Stage III Cutaneous Melanoma AJCC v8;   Pathologic Stage IIIA Cutaneous Melanoma AJCC v8;   Pathologic Stage IIIB Cutaneous Melanoma AJCC v8;   Pathologic Stage IIIC Cutaneous Melanoma AJCC v8;   Pathologic Stage IIID Cutaneous Melanoma AJCC v8;   Pathologic Stage IV Cutaneous Melanoma AJCC v8
  Interventions:   Biological: Pembrolizumab;   Procedure: Therapeutic Conventional Surgery
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• Ibrutinib Before and After Stem Cell Transplant in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma

  NCT02443077

  Conditions:   Recurrent Diffuse Large B-Cell Lymphoma Activated B-Cell Type;   Refractory Diffuse Large B-Cell Lymphoma Activated B-Cell Type
  Interventions:   Procedure: Autologous Bone Marrow Transplantation;   Procedure: Autologous Hematopoietic Stem Cell Transplantation;   Drug: Carmustine;   Drug: Cyclophosphamide;   Drug: Cytarabine;   Drug: Etoposide;   Drug: Ibrutinib;   Other: Laboratory Biomarker Analysis;   Drug: Melphalan;   Other: Pharmacogenomic Study;   Other: Placebo Administration
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• Cediranib Maleate and Olaparib or Standard Chemotherapy in Treating Patients With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

  NCT02502266

  Conditions:   Fallopian Tube Clear Cell Adenocarcinoma;   Fallopian Tube Endometrioid Adenocarcinoma;   Fallopian Tube Serous Adenocarcinoma;   Fallopian Tube Transitional Cell Carcinoma;   Fallopian Tube Undifferentiated Carcinoma;   Ovarian Clear Cell Adenocarcinoma;   Ovarian Endometrioid Adenocarcinoma;   Ovarian Seromucinous Carcinoma;   Ovarian Serous Adenocarcinoma;   Ovarian Transitional Cell Carcinoma;   Ovarian Undifferentiated Carcinoma;   Primary Peritoneal Serous Adenocarcinoma;   Recurrent Fallopian Tube Carcinoma;   Recurrent Ovarian Carcinoma;   Recurrent Primary Peritoneal Carcinoma
  Interventions:   Drug: Cediranib;   Drug: Cediranib Maleate;   Drug: Olaparib;   Drug: Paclitaxel;   Drug: Pegylated Liposomal Doxorubicin Hydrochloride;   Other: Questionnaire Administration;   Drug: Topotecan;   Drug: Topotecan Hydrochloride
  Sponsors:   National Cancer Institute (NCI);   NRG Oncology
  Recruiting
• Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer

  NCT02488967

  Conditions:   Breast Adenocarcinoma;   Estrogen Receptor Negative;   HER2/Neu Negative;   Progesterone Receptor Negative;   Stage IB Breast Cancer;   Stage IIA Breast Cancer;   Stage IIB Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIC Breast Cancer;   Triple-Negative Breast Carcinoma
  Interventions:   Drug: Carboplatin;   Drug: Cyclophosphamide;   Drug: Doxorubicin Hydrochloride;   Other: Laboratory Biomarker Analysis;   Drug: Paclitaxel
  Sponsors:   NRG Oncology;   National Cancer Institute (NCI)
  Recruiting
• S1702 Isatuximab in Treating Patients With Relapsed or Refractory Primary Amyloidosis

  NCT03499808

  Conditions:   Amorphous, Eosinophilic, and Acellular Deposit;   Constipation;   Diarrhea;   Early Satiety;   Gastrointestinal Hemorrhage;   Hepatomegaly;   Lymphadenopathy;   Macroglossia;   Nausea;   Primary Systemic Amyloidosis;   Purpura;   Recurrent Primary Amyloidosis;   Refractory Primary Amyloidosis
  Interventions:   Biological: Isatuximab;   Other: Laboratory Biomarker Analysis
  Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
  Recruiting
• Hypofractionated Radiation Therapy After Mastectomy in Preventing Recurrence in Patients With Stage IIa-IIIa Breast Cancer

  NCT03414970

  Conditions:   Ductal Breast Carcinoma;   Invasive Breast Carcinoma;   Lobular Breast Carcinoma;   Medullary Breast Carcinoma;   Stage II Breast Cancer;   Stage IIA Breast Cancer;   Stage IIB Breast Cancer;   Stage IIIA Breast Cancer;   Tubular Breast Carcinoma
  Interventions:   Radiation: Radiation Therapy;   Other: Questionnaire Administration;   Other: Quality-of-Life Assessment;   Other: Laboratory Biomarker Analysis;   Radiation: Hypofractionated Radiation Therapy
  Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI);   Canadian Cancer Trials Group
  Recruiting
• Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)

  NCT02194738

  Conditions:   Lung Adenocarcinoma;   Lung Large Cell Carcinoma;   Resectable Lung Non-Small Cell Carcinoma;   Stage IB Lung Non-Small Cell Carcinoma AJCC v7;   Stage IB Lung Squamous Cell Carcinoma AJCC v7;   Stage II Lung Non-Small Cell Cancer AJCC v7;   Stage II Lung Squamous Cell Carcinoma AJCC v7;   Stage IIA Lung Non-Small Cell Carcinoma AJCC v7;   Stage IIA Lung Squamous Cell Carcinoma AJCC v7;   Stage IIB Lung Non-Small Cell Carcinoma AJCC v7;   Stage IIB Lung Squamous Cell Carcinoma AJCC v7;   Stage IIIA Lung Non-Small Cell Cancer AJCC v7;   Stage IIIA Lung Squamous Cell Carcinoma AJCC v7
  Interventions:   Other: Clinical Observation;   Drug: Crizotinib;   Other: Cytology Specimen Collection Procedure;   Drug: Erlotinib;   Drug: Erlotinib Hydrochloride;   Biological: Nivolumab;   Other: Placebo Administration
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial)

  NCT02193282

  Conditions:   EGFR Exon 19 Deletion Mutation;   EGFR NP_005219.2:p.L858R;   Stage IB Lung Non-Small Cell Carcinoma AJCC v7;   Stage II Lung Non-Small Cell Cancer AJCC v7;   Stage IIA Lung Non-Small Cell Carcinoma AJCC v7;   Stage IIB Lung Non-Small Cell Carcinoma AJCC v7;   Stage IIIA Lung Non-Small Cell Cancer AJCC v7
  Interventions:   Other: Clinical Observation;   Drug: Erlotinib;   Drug: Erlotinib Hydrochloride;   Other: Laboratory Biomarker Analysis;   Other: Placebo Administration
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma

  NCT02224781

  Conditions:   Metastatic Melanoma;   Recurrent Melanoma;   Stage III Cutaneous Melanoma AJCC v7;   Stage IIIA Cutaneous Melanoma AJCC v7;   Stage IIIB Cutaneous Melanoma AJCC v7;   Stage IIIC Cutaneous Melanoma AJCC v7;   Stage IV Cutaneous Melanoma AJCC v6 and v7;   Unresectable Cutaneous Melanoma
  Interventions:   Drug: Dabrafenib;   Drug: Dabrafenib Mesylate;   Biological: Ipilimumab;   Biological: Nivolumab;   Other: Quality-of-Life Assessment;   Drug: Trametinib;   Drug: Trametinib Dimethyl Sulfoxide
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• A Study of Talazoparib in Men With DNA Repair Defects and Metastatic Castration-Resistant Prostate Cancer

  NCT03148795

  Condition:   Prostate Cancer
  Intervention:   Drug: Talazoparib
  Sponsors:   Pfizer;   Medivation, Inc.
  Recruiting
• Naloxegol in Treating Patients With Stage IIIB-IV Non-small Cell Lung Cancer

  NCT03087708

  Conditions:   Stage IIIB Non-Small Cell Lung Cancer;   Stage IV Non-small Cell Lung Cancer
  Interventions:   Drug: Naloxegol;   Other: Placebo;   Other: Laboratory Biomarker Analysis;   Other: Quality-of-Life Assessment
  Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI)
  Recruiting
• Pembrolizumab in Treating Patients With Triple-Negative Breast Cancer

  NCT02954874

  Conditions:   Invasive Breast Carcinoma;   Stage 0 Breast Cancer AJCC v6 and v7;   Stage I Breast Cancer AJCC v7;   Stage IA Breast Cancer AJCC v7;   Stage IB Breast Cancer AJCC v7;   Stage II Breast Cancer AJCC v6 and v7;   Stage IIA Breast Cancer AJCC v6 and v7;   Stage IIB Breast Cancer AJCC v6 and v7;   Stage III Breast Cancer AJCC v7;   Stage IIIA Breast Cancer AJCC v7;   Stage IIIB Breast Cancer AJCC v7;   Stage IIIC Breast Cancer AJCC v7;   Triple-Negative Breast Carcinoma
  Interventions:   Other: Laboratory Biomarker Analysis;   Other: Patient Observation;   Biological: Pembrolizumab;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration;   Radiation: Radiation Therapy
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• S0820, Adenoma and Second Primary Prevention Trial

  NCT01349881

  Condition:   Colorectal Neoplasms
  Interventions:   Drug: Eflornithine placebo & sulindac placebo;   Drug: eflornithine & sulindac placebo;   Drug: Eflornithine placebo & sulindac;   Drug: Eflornithine plus sulindac
  Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI);   Cancer Prevention Pharmaceuticals, Inc.
  Recruiting
• Vitamin D3 With Chemotherapy and Bevacizumab in Treating Patients With Advanced or Metastatic Colorectal Cancer

  NCT04094688

  Condition:   Colorectal Adenocarcinoma
  Interventions:   Drug: Bevacizumab;   Drug: Oxaliplatin;   Drug: Leucovorin Calcium;   Drug: Fluorouracil;   Drug: Irinotecan Hydrochloride;   Drug: Irinotecan;   Dietary Supplement: Cholecalciferol;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration
  Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI)
  Recruiting
• Docetaxel or Paclitaxel in Reducing Chemotherapy-Induced Peripheral Neuropathy in African American Patients With Stage I-III Breast Cancer

  NCT04001829

  Conditions:   Anatomic Stage I Breast Cancer AJCC v8;   Anatomic Stage IA Breast Cancer AJCC v8;   Anatomic Stage IB Breast Cancer AJCC v8;   Anatomic Stage II Breast Cancer AJCC v8;   Anatomic Stage IIA Breast Cancer AJCC v8;   Anatomic Stage IIB Breast Cancer AJCC v8;   Anatomic Stage III Breast Cancer AJCC v8;   Anatomic Stage IIIA Breast Cancer AJCC v8;   Anatomic Stage IIIB Breast Cancer AJCC v8;   Anatomic Stage IIIC Breast Cancer AJCC v8;   Invasive Breast Carcinoma;   Prognostic Stage I Breast Cancer AJCC v8;   Prognostic Stage IA Breast Cancer AJCC v8;   Prognostic Stage IB Breast Cancer AJCC v8;   Prognostic Stage II Breast Cancer AJCC v8;   Prognostic Stage IIA Breast Cancer AJCC v8;   Prognostic Stage IIB Breast Cancer AJCC v8;   Prognostic Stage III Breast Cancer AJCC v8;   Prognostic Stage IIIA Breast Cancer AJCC v8;   Prognostic Stage IIIB Breast Cancer AJCC v8;   Prognostic Stage IIIC Breast Cancer AJCC v8
  Interventions:   Drug: Docetaxel;   Drug: Paclitaxel;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration
  Sponsors:   ECOG-ACRIN Cancer Research Group;   National Cancer Institute (NCI)
  Recruiting
• Genetic Testing in Guiding Treatment for Patients With Brain Metastases

  NCT03994796

  Conditions:   CDK Gene Mutation;   Metastatic Malignant Neoplasm in the Brain;   Metastatic Malignant Solid Neoplasm;   NTRK Family Gene Mutation;   PI3K Gene Mutation;   ROS1 Gene Mutation
  Interventions:   Drug: Abemaciclib;   Drug: PI3K Inhibitor GDC-0084;   Drug: Entrectinib
  Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI);   Genentech, Inc.
  Recruiting
• Testing the Addition of a New Anti-cancer Drug, Venetoclax, to Usual Chemotherapy for High Grade B-cell Lymphomas

  NCT03984448

  Conditions:   Diffuse Large B-Cell Lymphoma;   Double-Expressor Lymphoma;   High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements;   High Grade B-Cell Lymphoma, Not Otherwise Specified;   Neoplastic Cells With Double Expression of MYC and BCL2 Proteins Present
  Interventions:   Drug: Cyclophosphamide;   Drug: Doxorubicin;   Drug: Doxorubicin Hydrochloride;   Drug: Etoposide;   Drug: Prednisone;   Biological: Rituximab;   Drug: Venetoclax;   Drug: Vincristine;   Drug: Vincristine Sulfate
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• Avelumab With or Without Cetuximab in Treating Patients With Advanced Skin Squamous Cell Cancer

  NCT03944941

  Conditions:   Skin Squamous Cell Carcinoma;   Metastatic Skin Cancer
  Interventions:   Drug: Avelumab;   Drug: Cetuximab
  Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI)
  Recruiting
• Pomalidomide and Dexamethasone With or Without Ixazomib in Treating Patients With Relapsed Multiple Myeloma

  NCT02004275

  Condition:   Multiple Myeloma in Relapse
  Interventions:   Drug: pomalidomide;   Drug: ixazomib;   Drug: dexamethasone
  Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI);   Celgene Corporation;   Millennium Pharmaceuticals, Inc.
  Recruiting
• Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors

  NCT03866382

  Conditions:   Bladder Adenocarcinoma;   Bladder Mixed Adenocarcinoma;   Bladder Small Cell Carcinoma;   Bladder Squamous Cell Carcinoma;   Chromophobe Renal Cell Carcinoma;   Infiltrating Bladder Lymphoepithelioma-Like Carcinoma;   Infiltrating Bladder Urothelial Carcinoma;   Infiltrating Bladder Urothelial Carcinoma With Giant Cells;   Infiltrating Bladder Urothelial Carcinoma, Nested Variant;   Infiltrating Bladder Urothelial Carcinoma, Plasmacytoid Variant;   Infiltrating Bladder Urothelial Carcinoma, Sarcomatoid Variant;   Kidney Medullary Carcinoma;   Large Cell Neuroendocrine Carcinoma;   Metastatic Bladder Carcinoma;   Metastatic Bladder Large Cell Neuroendocrine Carcinoma;   Metastatic Bladder Small Cell Carcinoma;   Metastatic Bladder Squamous Cell Carcinoma;   Metastatic Infiltrating Bladder Urothelial Carcinoma, Clear Cell Variant;   Metastatic Infiltrating Bladder Urothelial Carcinoma, Lipid-Rich Variant;   Metastatic Infiltrating Bladder Urothelial Carcinoma, Micropapillary Variant;   Metastatic Infiltrating Bladder Urothelial Carcinoma, Plasmacytoid Variant;   Metastatic Infiltrating Bladder Urothelial Carcinoma, Sarcomatoid Variant;   Metastatic Kidney Medullary Carcinoma;   Metastatic Malignant Genitourinary System Neoplasm;   Metastatic Penile Carcinoma;   Metastatic Prostate Small Cell Carcinoma;   Metastatic Sarcomatoid Renal Cell Carcinoma;   Papillary Renal Cell Carcinoma;   Sarcomatoid Renal Cell Carcinoma;   Stage IV Bladder Cancer AJCC v8;   Stage IV Penile Cancer AJCC v8;   Stage IV Prostate Cancer AJCC v8;   Stage IV Renal Cell Cancer AJCC v8;   Stage IVA Bladder Cancer AJCC v8;   Stage IVA Prostate Cancer AJCC v8;   Stage IVB Bladder Cancer AJCC v8;   Stage IVB Prostate Cancer AJCC v8;   Testicular Leydig Cell Tumor;   Testicular Sertoli Cell Tumor
  Interventions:   Drug: Cabozantinib;   Drug: Cabozantinib S-malate;   Biological: Ipilimumab;   Biological: Nivolumab
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• Testing Maintenance Immunotherapy Versus Observation in Patients With Oropharynx Cancer

  NCT03811015

  Conditions:   Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8;   Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8;   Pathologic Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8;   Pathologic Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8
  Interventions:   Drug: Cisplatin;   Radiation: Intensity-Modulated Radiation Therapy;   Biological: Nivolumab;   Other: Patient Observation
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study

  NCT03793166

  Conditions:   Clear Cell Renal Cell Carcinoma;   Metastatic Malignant Neoplasm in Lymph Node;   Metastatic Malignant Neoplasm in the Bone;   Metastatic Malignant Neoplasm in the Soft Tissues;   Metastatic Malignant Neoplasm in the Viscera;   Sarcomatoid Renal Cell Carcinoma;   Stage IV Renal Cell Cancer AJCC v8
  Interventions:   Drug: Cabozantinib;   Biological: Ipilimumab;   Biological: Nivolumab;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• Pembrolizumab Compared to Standard of Care Observation in Treating Patients With Completely Resected Stage I-III Merkel Cell Cancer

  NCT03712605

  Conditions:   Pathologic Stage I Merkel Cell Carcinoma AJCC v8;   Pathologic Stage II Merkel Cell Carcinoma AJCC v8;   Pathologic Stage IIA Merkel Cell Carcinoma AJCC v8;   Pathologic Stage IIB Merkel Cell Carcinoma AJCC v8;   Pathologic Stage III Merkel Cell Carcinoma AJCC v8;   Pathologic Stage IIIA Merkel Cell Carcinoma AJCC v8;   Pathologic Stage IIIB Merkel Cell Carcinoma AJCC v8
  Interventions:   Other: Best Practice;   Biological: Pembrolizumab;   Radiation: Radiation Therapy
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• Brentuximab Vedotin and Nivolumab With or Without Ipilimumab in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma

  NCT01896999

  Conditions:   Recurrent Classic Hodgkin Lymphoma;   Refractory Classic Hodgkin Lymphoma
  Interventions:   Drug: Brentuximab Vedotin;   Biological: Ipilimumab;   Biological: Nivolumab
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• Study Evaluating the Efficacy and Safety of Obeticholic Acid in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis

  NCT03439254

  Conditions:   Compensated Cirrhosis;   Nonalcoholic Steatohepatitis
  Interventions:   Drug: Obeticholic acid (10 mg);   Drug: Obeticholic acid (10 mg to 25 mg);   Drug: Placebo
  Sponsor:   Intercept Pharmaceuticals
  Recruiting
• AURORA: Phase 3 Study for the Efficacy and Safety of CVC for the Treatment of Liver Fibrosis in Adults With NASH

  NCT03028740

  Condition:   Nonalcoholic Steatohepatitis
  Interventions:   Drug: Cenicriviroc;   Drug: Placebo
  Sponsor:   Tobira Therapeutics, Inc.
  Recruiting
• The Comparison of Outcomes of Antibiotic Drugs and Appendectomy (CODA) Trial

  NCT02800785

  Condition:   Appendicitis
  Interventions:   Drug: Cefoxitin, Ertapenem, Moxifloxacin, Tigecycline, Ticarcillin-Clavulanic Acid; Metronidazole plus Cefazolin, Cefuroxime, Ceftriaxone, Cefotaxime, Ciprofloxacin, or Levofloxacin;   Procedure: Appendectomy
  Sponsors:   University of Washington;   Patient-Centered Outcomes Research Institute
  Recruiting
• Cabozantinib S-Malate, Crizotinib, Savolitinib, or Sunitinib Malate in Treating Patients With Locally Advanced or Metastatic Kidney Cancer

  NCT02761057

  Conditions:   Stage III Renal Cell Cancer AJCC v7;   Stage IV Renal Cell Cancer AJCC v7;   Type 1 Papillary Renal Cell Carcinoma;   Type 2 Papillary Renal Cell Carcinoma;   Unresectable Renal Cell Carcinoma
  Interventions:   Drug: Cabozantinib;   Drug: Cabozantinib S-malate;   Drug: Crizotinib;   Drug: Savolitinib;   Drug: Sunitinib;   Drug: Sunitinib Malate
  Sponsors:   National Cancer Institute (NCI);   Canadian Cancer Trials Group
  Recruiting